<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ATORVASTATIN CALCIUM- atorvastatin calcium trihydrate tablet </strong><br>NCS HealthCare of KY, Inc dba Vangard Labs<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use atorvastatin calcium safely and effectively. See full prescribing information for atorvastatin calcium. </span><br><span class="Bold">Atorvastatin Calcium Tablets for oral administration</span><span class="Bold"> </span><br><span class="Bold">Initial U.S. Approval: 1996</span>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Dosage and Administration <a href="#LINK_cbab7c5b-7cd5-4809-8dd1-edffb204f98f">(2.6)</a>                                                   10/2012  </p>
<p class="Highlighta">Warnings and Precautions <a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a>                                                    10/2012  </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Atorvastatin calcium tablet is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to:  </p>
<ul class="Disk">
<li>Reduce the risk of MI, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, revascularization procedures, and angina in patients without CHD, but with multiple risk factors <a href="#LINK_6d090665-af6a-4101-bde6-34ff749eeca8">(1.1)</a>.

</li>
<li>Reduce the risk of MI and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> without CHD, but with multiple risk factors (1.1).

</li>
<li>Reduce the risk of non-fatal MI, fatal and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, revascularization procedures, hospitalization for CHF, and angina in patients with CHD (1.1).

</li>
<li>Reduce elevated total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, and TG levels and increase HDL-C in adult patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> (heterozygous familial and nonfamilial) and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> <a href="#LINK_8d9162b7-bcac-43d8-9987-777b829601be">(1.2)</a>.

</li>
<li>Reduce elevated TG in patients with <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> and primary dysbetalipoproteinemia <a href="#LINK_8d9162b7-bcac-43d8-9987-777b829601be">(1.2)</a>.

</li>
<li>Reduce total-C and LDL-C in patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span> (HoFH) <a href="#LINK_8d9162b7-bcac-43d8-9987-777b829601be">(1.2)</a>.

</li>
<li>Reduce elevated total-C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span> levels in boys and postmenarchal girls, 10 to 17 years of age, with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> after failing an adequate trial of diet therapy <a href="#LINK_8d9162b7-bcac-43d8-9987-777b829601be">(1.2)</a>. </li>
</ul>
<p class="Highlighta">Limitations of Use </p>
<p class="Highlighta">Atorvastatin calcium tablets have not been studied in <span class="Italics">Fredrickson</span> Types I and V <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>. </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Dose range: 10 to 80 mg once daily <a href="#LINK_34340c16-a965-4b88-9c3e-7be622a8917b">(2.1)</a>.  </p>
<p class="Highlighta">Recommended start dose: 10 or 20 mg once daily <a href="#LINK_34340c16-a965-4b88-9c3e-7be622a8917b">(2.1)</a>.  </p>
<p class="Highlighta">Patients requiring large LDL-C reduction (&gt;45%) may start at 40 mg once daily <a href="#LINK_34340c16-a965-4b88-9c3e-7be622a8917b">(2.1)</a>.  </p>
<p class="Highlighta">Pediatric starting dose: 10 mg once daily; maximum recommended dose: 20 mg once daily <a href="#LINK_d4e25197-9325-4d3b-bcb8-737acc0b22a8">(2.2)</a>. </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">80 mg tablets <a href="#LINK_9681167a-b1f9-4df2-9a3f-d848c0438164">(3)</a>. </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels <a href="#LINK_11804937-b221-4d89-8f10-da587cc69a1d">(4.1)</a>.  </p>
<p class="Highlighta">Women who are pregnant or may become pregnant <a href="#LINK_9b857776-e7f6-4b22-9ff6-813352f0c37b">(4.3)</a>. </p>
<p class="Highlighta">Nursing mothers <a href="#LINK_a9202810-102e-43b9-88f3-a3213eb5dd44">(4.4).</a> </p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication <a href="#LINK_11804937-b221-4d89-8f10-da587cc69a1d">(4.2)</a>. </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">Skeletal muscle effects (e.g., <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>): Risks increase when higher doses are used concomitantly with cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors). Predisposing factors include advanced age (&gt; 65), uncontrolled <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> have been reported. Advise patients to promptly report to their physician unexplained and/or persistent <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Atorvastatin calcium therapy should be discontinued if <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected (<a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">5.1</a>, <a href="#LINK_b069e87b-d6db-43c0-a404-51b8da24524a">8.5</a>). </p>
<p class="Highlighta">Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter <a href="#LINK_1b3efc6e-4d47-4753-8311-0f068032db18">(5.2)</a>. </p>
<p class="Highlighta">A higher incidence of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was seen in patients without CHD but with <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA within the previous 6 months in the atorvastatin calcium 80 mg group vs. placebo <a href="#LINK_d87d5469-0d15-4173-b7a7-8a2621775eb3">(5.5)</a>. </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most commonly reported adverse reactions (incidence ≥ 2%) in patients treated with atorvastatin calcium in placebo-controlled trials regardless of causality were: <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> <a href="#LINK_0c0d66d6-c652-421e-adc2-1041b1a7459b">(6.1).</a> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact </span><span class="Bold">Dr. Reddy’s Laboratories Inc., at 1-888-375-3784 </span><span class="Bold">or FDA at 1-800-FDA-1088 or </span><span class="Bold">www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">Drug Interactions Associated with Increased Risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> (<a href="#LINK_cbab7c5b-7cd5-4809-8dd1-edffb204f98f">2.6</a>, <a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">5.1</a>, <a href="#LINK_f7e3557d-3311-4995-a78d-69e34f73342a">7</a>, <a href="#LINK_8bcc8dce-4b63-48eb-8eb9-cbec4e0650c0">12.3</a>) </p>
<table>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td> Interacting Agents </td>
<td> Prescribing Recommendations </td>
</tr>
<tr>
<td> Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor (telaprevir) </td>
<td> Avoid atorvastatin</td>
</tr>
<tr>
<td> HIV protease inhibitor (lopinavir plus ritonavir) </td>
<td> Use with caution and lowest dose necessary</td>
</tr>
<tr>
<td> Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir) </td>
<td> Do not exceed 20 mg atorvastatin daily</td>
</tr>
<tr class="Last">
<td> HIV protease inhibitors (nelfinavir) <br><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C protease inhibitor (boceprevir)</td>
<td> Do not exceed 40 mg atorvastatin daily</td>
</tr>
</tbody>
</table>
<ul class="Disk">
<li>Other Lipid-Lowering Medications: Use with fibrate products or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with atorvastatin calcium <a href="#LINK_f7e3557d-3311-4995-a78d-69e34f73342a">(7)</a>.</li>
<li>Digoxin: Patients should be monitored appropriately <a href="#LINK_1133fdd2-efec-418f-8f06-3a6a7c76f402">(7.8)</a>.</li>
<li>Oral Contraceptives: Values for norethindrone and ethinyl estradiol may be increased <a href="#LINK_f7519767-5e7a-447d-b700-57ee6129f06a">(7.9)</a>.</li>
<li>Rifampin should be simultaneously co-administered with atorvastatin calcium <a href="#LINK_f8d590c2-30d3-4cbf-a675-26041cc6821f">(7.7)</a>.</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk"><li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>: Plasma concentrations markedly increased in patients with chronic <span class="product-label-link" type="condition" conceptid="201612" conceptname="Alcoholic liver damage">alcoholic liver disease</span> <a href="#LINK_8bcc8dce-4b63-48eb-8eb9-cbec4e0650c0">(12.3)</a>.</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div><div></div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 1/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1 INDICATIONS AND USAGE</span></a></h1>
<h2><a href="#section-1.1" class="toc"><span class="Bold">1.1 Prevention of Cardiovascular Disease</span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="Bold">1.2 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></span></a></h2>
<h2><a href="#section-1.3" class="toc"><span class="Bold">1.3 Limitations of Use</span></a></h2>
<h1><a href="#section-2" class="toc"><span class="Bold">2 DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> (<span class="Italics">Fredrickson</span> Types IIa and IIb)</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients (10-17 years of age)</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.3 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.4 Concomitant Lipid-Lowering Therapy</span></a></h2>
<h2><a href="#section-2.5" class="toc"><span class="Bold">2.5 Dosage in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></a></h2>
<h2><a href="#section-2.6" class="toc"><span class="Bold">2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3 DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4 CONTRAINDICATIO</span>NS</a></h1>
<h2><a href="#section-4.1" class="toc"><span class="Bold">4.1</span> Active liver disease which may include unexplained persistent elevations of hepatic transminase levels</a></h2>
<h2><a href="#section-4.2" class="toc"><span class="Bold">4.2</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any Component of this Medication</a></h2>
<h2><a href="#section-4.3" class="toc"><span class="Bold">4.3</span> Pregnancy</a></h2>
<h2><a href="#section-4.4" class="toc"><span class="Bold">4.4 Nursing mothers</span></a></h2>
<h1><a href="#section-5" class="toc"><span class="Bold">5 WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 Skeletal Muscle</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 Liver Dysfunction</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3 Endocrine Function</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 CNS Toxicity</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5 Use in Patients with Recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or TIA</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 Clinical Trial Adverse Experiences</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2 Postmarketing Experience</span></a></h2>
<h2><a href="#section-6.3" class="toc"><span class="Bold">6.3 Pediatric Patients (ages 10-17 years)</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7 DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1 Strong Inhibitors of CYP 3A4</span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold">7.2 Grapefruit Juice</span></a></h2>
<h2><a href="#section-7.3" class="toc"><span class="Bold">7.3 Cyclosporine</span></a></h2>
<h2><a href="#section-7.4" class="toc"><span class="Bold">7.4 Gemfibrozil</span></a></h2>
<h2><a href="#section-7.5" class="toc"><span class="Bold">7.5 Other Fibrates</span></a></h2>
<h2><a href="#section-7.6" class="toc"><span class="Bold">7.6 Niacin</span></a></h2>
<h2><a href="#section-7.7" class="toc"><span class="Bold">7.7 Rifampin or other Inducers of Cytochrome P450 3A4</span></a></h2>
<h2><a href="#section-7.8" class="toc"><span class="Bold">7.8 Digoxin</span></a></h2>
<h2><a href="#section-7.9" class="toc"><span class="Bold">7.9 Oral Contraceptives</span></a></h2>
<h2><a href="#section-7.10" class="toc"><span class="Bold">7.10 Warfarin</span></a></h2>
<h2><a href="#section-7.11" class="toc"><span class="Bold">7.11 Colchicine</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8 USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1 Pregnancy</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.3 Nursing Mothers</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.4 Pediatric Use</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.5 Geriatric Use</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10 OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11 DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12 CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1 Mechanism of Action</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.2 Pharmacodynamics</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.3 Pharmacokinetics</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13 NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14 CLINICAL STUDIES</span></a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">14.1 Prevention of Cardiovascular Disease </span></a></h2>
<h2><a href="#section-13.2" class="toc"><span class="Bold">14.2 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> (</span><span class="Bold"><span class="Italics">Fredrickson</span></span><span class="Bold"> Types IIa and IIb)</span></a></h2>
<h2><a href="#section-13.3" class="toc"><span class="Bold">14.3 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> (</span><span class="Bold"><span class="Italics">Fredrickson </span></span><span class="Bold">Type IV) </span></a></h2>
<h2><a href="#section-13.4" class="toc"><span class="Bold">14.4 Dysbetalipoproteinemia </span></a></h2>
<h2><a href="#section-13.5" class="toc"><span class="Bold">14.5 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> </span></a></h2>
<h2><a href="#section-13.6" class="toc"><span class="Bold">14.6 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients </span></a></h2>
<h1><a href="#section-14" class="toc"><span class="Bold">15 REFERENCES</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">16 HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h1><a href="#section-16" class="toc"><span class="Bold">17 PATIENT COUNSELING INFORMATION</span></a></h1>
<h2><a href="#section-16.1" class="toc"><span class="Bold">17.1 <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span> </span></a></h2>
<h2><a href="#section-16.2" class="toc"><span class="Bold">17.2 Liver Enzymes </span></a></h2>
<h2><a href="#section-16.3" class="toc"><span class="Bold"><span class="Bold">17.3 Pregnancy </span></span></a></h2>
<h2><a href="#section-16.4" class="toc"><span class="Bold">17.4 Breast-feeding </span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_bba7f8c3-5d0d-476c-b33b-6e7c3c336afb"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">1 INDICATIONS AND USAGE</span></h1>
<p class="First">Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cb6f921a-4fed-4200-95c4-16c57a721e6e"></a><a name="section-1.1"></a><p></p>
<h2><span class="Bold">1.1 Prevention of Cardiovascular Disease</span></h2>
<p class="First">In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: </p>
<ul class="Disk">
<li>Reduce the risk of myocardial infarction     

</li>
<li>Reduce the risk of stroke     

</li>
<li>Reduce the risk for revascularization procedures and angina</li>
</ul>
<p>In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, smoking, or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, atorvastatin calcium tablets are indicated to:</p>
<ul class="Disk">
<li>Reduce the risk of myocardial infarction     

</li>
<li>Reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
</ul>
<p>In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to:</p>
<ul class="Disk">
<li>Reduce the risk of non-fatal myocardial infarction     

</li>
<li>Reduce the risk of fatal and non-fatal stroke     

</li>
<li>Reduce the risk for revascularization procedures     

</li>
<li>Reduce the risk of hospitalization for CHF     

</li>
<li>Reduce the risk of angina</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d3204d01-a9fa-4ce6-a4cf-b5b4f9fe4b71"></a><a name="section-1.2"></a><p></p>
<h2><span class="Bold">1.2 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></span></h2>
<p class="First">Atorvastatin calcium tablets are indicated: </p>
<ul class="Disk">
<li>As an adjunct to diet to reduce elevated total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, and TG levels and to increase HDL-C in patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> (heterozygous familial and nonfamilial) and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> (<span class="Italics">Fredrickson </span>Types IIa and IIb); 

</li>
<li>As an adjunct to diet for the treatment of patients with elevated serum TG levels (<span class="Italics">Fredrickson </span>Type IV); 

</li>
<li>For the treatment of patients with primary dysbetalipoproteinemia (<span class="Italics">Fredrickson </span>Type III) who do not respond adequately to diet; 

</li>
<li>To reduce total-C and LDL-C in patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span> as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 

</li>
<li>As an adjunct to diet to reduce total-C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span> levels in boys and postmenarchal girls, 10 to 17 years of age, with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> if after an adequate trial of diet therapy the following findings are present:              </li>
</ul>
<p>a. LDL-C remains ≥ 190 mg/dL or            </p>
<p>b. LDL-C remains ≥ 160 mg/dL and: </p>
<ul class="Disk">
<li>there is a positive family history of premature cardiovascular disease or 

</li>
<li>two or more other CVD risk factors are present in the pediatric patient  </li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e03b1ce5-b24b-47ab-8098-cc0ea99a276e"></a><a name="section-1.3"></a><p></p>
<h2><span class="Bold">1.3 Limitations of Use</span></h2>
<p class="First">Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (<span class="Italics">Fredrickson </span>Types I and V).</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_f16eb047-d8a5-48af-a849-5270144d8b21"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">2 DOSAGE AND ADMINISTRATION</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_11979fe5-45b6-4666-ab94-7ec5fe771325"></a><a name="section-2.1"></a><p></p>
<h2><span class="Bold">2.1 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> (<span class="Italics">Fredrickson</span> Types IIa and IIb)</span></h2>
<p class="First">The recommended starting dose of atorvastatin calcium tablets is 10 or 20 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily. The dosage range of atorvastatin calcium tablets is 10 to 80 mg once daily. Atorvastatin calcium tablets can be administered as a single dose at any time of the day, with or without food. The starting dose and maintenance doses of atorvastatin calcium tablets should be individualized according to patient characteristics such as goal of therapy and response (see current NCEP Guidelines). After initiation and/or upon titration of atorvastatin calcium tablets, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b1be7c5b-5294-46f6-9e64-43984a5d31e8"></a><a name="section-2.2"></a><p></p>
<h2><span class="Bold">2.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients (10-17 years of age)</span></h2>
<p class="First">The recommended starting dose of atorvastatin calcium tablets is 10 mg/day; the maximum recommended dose is 20 mg/day (doses greater than 20 mg have not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy [see <span class="Bold">current NCEP Pediatric Panel Guidelines, Clinical Pharmacology </span><span class="Bold"><a href="#LINK_76592937-08e6-44b6-a484-ba3edc4a5611">(12)</a></span><span class="Bold">, </span>and<span class="Bold"> Indications and Usage (<a href="#LINK_8d9162b7-bcac-43d8-9987-777b829601be">1.2)</a></span>]. Adjustments should be made at intervals of 4 weeks or more. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_90c70fab-6186-4086-b9f4-aaeb90ed92c8"></a><a name="section-2.3"></a><p></p>
<h2><span class="Bold">2.3 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></span></h2>
<p class="First">The dosage of atorvastatin calcium tablets in patients with homozygous FH is 10 to 80 mg daily. Atorvastatin calcium tablets should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a806b46a-96e3-410a-afee-a4e983fa9a2b"></a><a name="section-2.4"></a><p></p>
<h2><span class="Bold">2.4 Concomitant Lipid-Lowering Therapy</span></h2>
<p class="First">Atorvastatin calcium tablets may be used with bile acid resins. The combination of HMG-CoA reductase inhibitors (statins) and fibrates should generally be used with caution [see <span class="Bold">Warnings and Precautions, Skeletal Muscle <a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a>, Drug Interactions <a href="#LINK_f7e3557d-3311-4995-a78d-69e34f73342a">(7)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_502c6f47-a515-4998-acaa-0e8f7658c2e7"></a><a name="section-2.5"></a><p></p>
<h2><span class="Bold">2.5 Dosage in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal disease</span> does not affect the plasma concentrations nor LDL-C reduction of atorvastatin calcium tablets; thus, dosage adjustment in patients with renal dysfunction is not necessary [see <span class="Bold">Warnings and Precautions, Skeletal Muscle <a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a>, Clinical Pharmacology, Pharmacokinetics <a href="#LINK_8bcc8dce-4b63-48eb-8eb9-cbec4e0650c0">(12.3)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2787aa83-c427-439a-a601-9a59511970c2"></a><a name="section-2.6"></a><p></p>
<h2><span class="Bold">2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors</span></h2>
<p class="First">In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor (telaprevir), therapy with atorvastatin calcium tablets should be avoided. In patients with HIV taking lopinavir plus ritonavir, caution should be used when prescribing atorvastatin calcium tablets and the lowest dose necessary employed. In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, therapy with atorvastatin calcium tablets should be limited to 20 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of atorvastatin calcium is employed. In patients taking the HIV protease inhibitor nelfinavir or the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor boceprevir, therapy with atorvastatin calcium tablets should be limited to 40 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of atorvastatin calcium tablets is employed [see <span class="Bold">Warnings and Precautions, Skeletal Muscle <a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a>, Drug Interactions <a href="#LINK_f7e3557d-3311-4995-a78d-69e34f73342a">(7)</a></span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_adecc300-bddb-43c7-908b-13a82efd4087"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">3 DOSAGE FORMS AND STRENGTHS</span></h1>
<p class="First">Atorvastatin calcium tablets of 80 mg are white to off-white, oval shaped, biconvex, film coated tablets debossed ‘RDY’on one side and ‘124’ on other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_6b1071b9-70aa-4024-869c-5fa67c213bf0"></a><a name="section-4"></a><p></p>
<h1>
<span class="Bold">4 CONTRAINDICATIO</span>NS</h1>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_e06f323e-82aa-4648-a8d1-d9d9a7b16dae"></a><a name="section-4.1"></a><p></p>
<h2>
<span class="Bold">4.1</span> Active liver disease which may include unexplained persistent elevations of hepatic transminase levels</h2>
<p class="First">Active liver disease which may include unexplained persistent elevations of hepatic transminase levels </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_532cd71f-5769-4646-9169-deb596b4b4b3"></a><a name="section-4.2"></a><p></p>
<h2>
<span class="Bold">4.2</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any Component of this Medication</h2>
<p class="First"><span class="Bold"> </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_0ea9010c-8d6c-49ef-b560-2b1784751352"></a><a name="section-4.3"></a><p></p>
<h2>
<span class="Bold">4.3</span> Pregnancy</h2>
<p class="First">Women who are pregnant or may become pregnant. Atorvastatin calcium may cause fetal harm when administered to a pregnant woman. Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> derivatives are essential for fetal development. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. There are no adequate and well-controlled studies of atorvastatin calcium use during pregnancy; however in rare reports, congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. ATORVASTATIN CALCIUM SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this drug, atorvastatin calcium should be discontinued immediately and the patient apprised of the potential hazard to the fetus [see <span class="Bold">Use in Specific Populations <a href="#LINK_353490d3-150f-4be6-8415-1599762af63a">(8.1</a><a href="#LINK_353490d3-150f-4be6-8415-1599762af63a">)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_c3874e3b-e97b-49e4-8a62-6fecb8c93301"></a><a name="section-4.4"></a><p></p>
<h2><span class="Bold">4.4 Nursing mothers</span></h2>
<p class="First">It is not known whether atorvastatin is excreted into human milk; however a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require atorvastatin calcium treatment should not breastfeed their infants [see <span class="Bold">Use in Specific Populations <a href="#LINK_3eea926f-fc0e-4350-895d-0d1bdf8c401b">(8.3)</a></span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_1ae7a498-f3d1-4c9f-b286-e67cfad5f0c3"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">5 WARNINGS AND PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_98527462-647d-4a2e-8a5e-9412aa619465"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">5.1 Skeletal Muscle</span></h2>
<p class="First"><span class="Bold">Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> have been reported with </span><span class="Bold">atorvastatin calcium </span><span class="Bold">and with other drugs in this class. </span>A history of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> may be a risk factor for the development of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. Such patients merit closer monitoring for skeletal muscle effects. </p>
<p>Atorvastatin, like other statins, occasionally causes <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, defined as <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span> or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in conjunction with increases in creatine phosphokinase (CPK) values &gt;10 times ULN. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. </p>
<p>There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (IMNM), an autoimmune <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, associated with statin use. IMNM is characterized by: proximal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> without significant <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>; improvement with immunosuppressive agents.</p>
<p><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> should be considered in any patient with diffuse <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, muscle <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and/or marked elevation of CPK. Patients should be advised to report promptly unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if muscle signs and symptoms persist after discontinuing atorvastatin. Atorvastatin calcium therapy should be discontinued if markedly elevated CPK levels occur or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir,  niacin, or azole antifungals. Physicians considering combined therapy with atorvastatin calcium and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs (see <span class="Bold">Drug Interactions <a href="#LINK_f7e3557d-3311-4995-a78d-69e34f73342a">(7)</a></span>). Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. </p>
<p>Prescribing recommendations for interacting agents are summarized in Table 1 [see <span class="Bold">also Dosage and Administration <a href="#LINK_cbab7c5b-7cd5-4809-8dd1-edffb204f98f">(2.6)</a>, Drug Interactions <a href="#LINK_f7e3557d-3311-4995-a78d-69e34f73342a">(7)</a>, Clinical Pharmacology <a href="#LINK_8bcc8dce-4b63-48eb-8eb9-cbec4e0650c0">(12.3)</a></span>].</p>
<p><span class="Bold">Table 1. Drug Interactions Associated with Increased Risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></span></p>
<table>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"> Interacting Agents </td>
<td class="Botrule Toprule"> Prescribing Recommendations </td>
</tr>
<tr>
<td class="Botrule Rrule"> Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor (telaprevir) </td>
<td class="Botrule"> Avoid atorvastatin</td>
</tr>
<tr>
<td class="Botrule Rrule"> HIV protease inhibitor (lopinavir plus ritonavir) </td>
<td class="Botrule"> Use with caution and lowest dose necessary </td>
</tr>
<tr>
<td class="Botrule Rrule"> Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir*, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir) </td>
<td class="Botrule"> Do not exceed 20 mg atorvastatin daily</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"> HIV protease inhibitor (nelfinavir) <br><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C protease inhibitor (boceprevir)</td>
<td class="Botrule"> Do not exceed 40 mg atorvastatin daily</td>
</tr>
</tbody>
</table>
<p>*Use with caution and with the lowest dose necessary (12.3) </p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine [see <span class="Bold">Drug Interactions </span><span class="Bold"><a href="#LINK_84b7c77c-b3b3-4871-8932-5ccad360398c">(7.11)</a></span>]</p>
<p><span class="Bold">Atorvastatin calcium therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> or having a risk factor predisposing to the development of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (e.g., severe acute <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, major surgery, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, severe metabolic, endocrine and electrolyte disorders, and uncontrolled <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>). </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_abaed905-73f2-402e-b869-a295cad6f4a9"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2 Liver Dysfunction</span></h2>
<p class="First">Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. <span class="Bold">Persistent elevations (&gt;3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin calcium in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively. </span></p>
<p>One patient in clinical trials developed <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. Increases in liver function tests (LFT) in other patients were not associated with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae. Eighteen of 30 patients with persistent LFT elevations continued treatment with a reduced dose of atorvastatin calcium. </p>
<p>It is recommended that liver enzyme tests be obtained prior to initiating therapy with atorvastatin calcium and repeated as clinically indicated. There have been rare postmarketing reports of fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients taking statins, including atorvastatin. If serious <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> with clinical symptoms and/or <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs during treatment with atorvastatin calcium, promptly interrupt therapy. If an alternate etiology is not found, do not restart atorvastatin calcium.</p>
<p>Atorvastatin calcium should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of atorvastatin calcium [see <span class="Bold">Contraindications <a href="#LINK_11804937-b221-4d89-8f10-da587cc69a1d">(4.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e522d4a6-bd70-4aad-b3ff-42c0a15e0e06"></a><a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3 Endocrine Function</span></h2>
<p class="First">Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including atorvastatin calcium.</p>
<p>Statins interfere with <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and theoretically might blunt adrenal and/or gonadal steroid production. Clinical studies have shown that atorvastatin calcium does not reduce basal plasma cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown. Caution should be exercised if a statin is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ec927dde-ab64-43db-bbae-336f2901021d"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4 CNS Toxicity</span></h2>
<p class="First">Brain <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> was seen in a female dog treated for 3 months at 120 mg/kg/day. Brain <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day. The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0-24 hours) based on the maximum human dose of 80 mg/day. A single <span class="product-label-link" type="condition" conceptid="4198075" conceptname="Tonic seizure">tonic convulsion</span> was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0-24) based on the maximum recommended human dose of 80 mg/day. </p>
<p>CNS vascular lesions, characterized by perivascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this class. A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_36692b12-beea-4bef-a5a9-230d7e005486"></a><a name="section-5.5"></a><p></p>
<h2><span class="Bold">5.5 Use in Patients with Recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or TIA</span></h2>
<p class="First">In a post-hoc analysis of the <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Prevention by Aggressive Reduction in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels (SPARCL) study where atorvastatin calcium 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA within the preceding 6 months, a higher incidence of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was seen in the atorvastatin calcium 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was similar across treatment groups (17 vs.18 for the atorvastatin and placebo groups, respectively). The incidence of nonfatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%). Some baseline characteristics, including hemorrhagic and lacunar <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> on study entry, were associated with a higher incidence of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> in the atorvastatin group [see <span class="Bold">Adverse Reactions <a href="#LINK_0c0d66d6-c652-421e-adc2-1041b1a7459b">(6.1)</a></span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_7668de67-6e8f-4198-932c-de4905cb4d1f"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the label: </p>
<p><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> and <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> [see <span class="Bold">Warnings and Precautions <a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a>] </span></p>
<p>Liver enzyme abnormalities<span class="Bold"> [see Warnings and Precautions <a href="#LINK_1b3efc6e-4d47-4753-8311-0f068032db18">(5.2)</a></span>] </p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e6c4ce8e-e634-47aa-bc60-7de2c80cdbaf"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">6.1 Clinical Trial Adverse Experiences</span></h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>In the atorvastatin calcium placebo-controlled clinical trial database of 16,066 patients (8755 atorvastatin calcium vs. 7311 placebo; age range 10–93 years, 39% women, 91% Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 9.7% of patients on atorvastatin calcium and 9.5% of the patients on placebo discontinued due to adverse reactions regardless of causality. The five most common adverse reactions in patients treated with atorvastatin calcium that led to treatment discontinuation and occurred at a rate greater than placebo were: <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (0.7%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (0.5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.4%), <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increase (0.4%), and hepatic enzyme increase (0.4%). </p>
<p>The most commonly reported adverse reactions (incidence ≥ 2% and greater than placebo) regardless of causality, in patients treated with atorvastatin calcium in placebo controlled trials (n=8755) were: <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (8.3%), <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (6.9%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (6.8%), <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span> (6.0%), and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (5.7%). </p>
<p>Table 2 summarizes the frequency of clinical adverse reactions, regardless of causality, reported in ≥ 2% and at a rate greater than placebo in patients treated with atorvastatin calcium (n=8755), from seventeen placebo-controlled trials.</p>
<table>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="7" valign="baseline"> <span class="Bold">Table 2. Clinical adverse reactions occurring in ≥ 2% in patients treated with any dose of atorvastatin calcium and at an incidence greater than placebo regardless of causality (% of patients).</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Adverse Reaction*</td>
<td class="Botrule Lrule Rrule Toprule"> Any dose N=8755</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 10 mg N=3908</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 20 mg N=188</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 40 mg N=604</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 80 mg N=4055</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Placebo N=7311</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 8.3</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 12.9</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 5.3</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 7.0</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 4.2</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 8.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 6.9</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 8.9</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 11.7</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 10.6</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 4.3</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 6.5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 6.8</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 7.3</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 6.4</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 14.1</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 5.2</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 6.3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 6.0</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 8.5</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.7</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 9.3</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.1</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 5.9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 5.7</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 6.9</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 6.4</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 8.0</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 4.1</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 5.6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 4.7</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 5.9</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.2</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 6.0</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.3</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 4.3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 4.0</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.7</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.7</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 7.1</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.8</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.8</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 5.2</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.2</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 5.1</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 2.3</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle Spasms</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.6</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 4.6</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 4.8</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 5.1</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 2.4</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.5</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.6</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 5.9</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 8.4</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 2.7</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.0</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 2.8</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 1.1</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 5.3</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 2.8</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 2.9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 2.3</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 3.9 </td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 1.6</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 2.8</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 0.7</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 2.1 </td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="7" valign="top"> * Adverse Reaction <span class="Bold">≥</span> 2% in any dose greater than placebo</td></tr>
</tbody>
</table>
<p>Other adverse reactions reported in placebo-controlled studies include: </p>
<p>Body as a whole: <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>; Digestive system: <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>; Musculoskeletal system: <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="4214612" conceptname="Muscle fatigue">muscle fatigue</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>; Metabolic and nutritional system: transaminases increase, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function test abnormal</span>, blood alkaline phosphatase increase, creatine phosphokinase increase, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>; Nervous system: <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmare</span>; Respiratory system: <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>; Skin and appendages: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; Special senses: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; Urogenital system: white blood cells urine positive. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6fe05f89-4729-41c0-9532-0f325c3ece69"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Italics">Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) </span></h3>
<p class="First">In ASCOT [see <span class="Bold">Clinical Studies <a href="#LINK_22d35ba6-37b6-45a6-8f3f-897874360741">(14.1)</a></span><span class="Bold">]</span> involving 10,305 participants (age range 40–80 years, 19% women; 94.6% Caucasians, 2.6% Africans, 1.5% South Asians, 1.3% mixed/other) treated with atorvastatin calcium 10 mg daily (n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group treated with atorvastatin calcium was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ffae2248-3860-4490-b957-4b485122640d"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Italics">Collaborative Atorvastatin <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Study (CARDS) </span></h3>
<p class="First">In CARDS [see <span class="Bold">Clinical Studies <a href="#LINK_22d35ba6-37b6-45a6-8f3f-897874360741">(14.1)</a></span>] involving 2,838 subjects (age range 39–77 years, 32% women; 94.3% Caucasians, 2.4% South Asians, 2.3% Afro-Caribbean, 1.0% other) with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> treated with atorvastatin calcium 10 mg daily (n=1,428) or placebo (n=1,410), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 3.9 years. No cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> were reported. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d554d870-a576-43f3-be34-10039abed1b0"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="Italics">Treating to New Targets Study (TNT) </span></h3>
<p class="First">In TNT [see <span class="Bold">Clinical Studies <a href="#LINK_22d35ba6-37b6-45a6-8f3f-897874360741">(14.1)</a></span>] involving 10,001 subjects (age range 29–78 years, 19% women; 94.1% Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident CHD treated with atorvastatin calcium 10 mg daily (n=5006) or atorvastatin calcium 80 mg daily (n=4995), there were more serious adverse reactions and discontinuations due to adverse reactions in the high-dose atorvastatin group (92, 1.8%; 497, 9.9%, respectively) as compared to the low-dose group (69, 1.4%; 404, 8.1%, respectively) during a median follow-up of 4.9 years. Persistent transaminase elevations (≥3 x ULN twice within 4–10 days) occurred in 62 (1.3%) individuals with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg. Elevations of CK (≥ 10 x ULN) were low overall, but were higher in the high-dose atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin group (6, 0.1%). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_aa8b2b57-1e58-4fe2-83db-1cd31a20609c"></a><a name="section-6.1.4"></a><p></p>
<h3><span class="Italics">Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study (IDEAL) </span></h3>
<p class="First">In IDEAL [see <span class="Bold">Clinical Studies <a href="#LINK_22d35ba6-37b6-45a6-8f3f-897874360741">(14.1)</a></span>] involving 8,888 subjects (age range 26–80 years, 19% women; 99.3% Caucasians, 0.4% Asians, 0.3% Blacks, 0.04% other) treated with atorvastatin calcium 80 mg/day (n=4439) or simvastatin 20–40 mg daily (n=4449), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 4.8 years. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c2a97bee-cca4-4d01-b384-04c11dd7de15"></a><a name="section-6.1.5"></a><p></p>
<h3><span class="Italics"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Prevention by Aggressive Reduction in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels (SPARCL) </span></h3>
<p class="First">In SPARCL involving 4731 subjects (age range 21–92 years, 40% women; 93.3% Caucasians, 3.0% Blacks, 0.6% Asians, 3.1% other) without clinically evident CHD but with a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or transient ischemic attack (TIA) within the previous 6 months treated with atorvastatin calcium  80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years, there was a higher incidence of persistent hepatic transaminase elevations (≥ 3 x ULN twice within 4–10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%). Elevations of CK (&gt;10 x ULN) were rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%). <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> was reported as an adverse reaction in 144 subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo group [see <span class="Bold">Warnings and Precautions <a href="#LINK_d87d5469-0d15-4173-b7a7-8a2621775eb3">(5.5)</a></span>]. </p>
<p>In a post-hoc analysis, atorvastatin calcium 80 mg reduced the incidence of <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> (218/2365, 9.2% vs. 274/2366, 11.6%) and increased the incidence of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> (55/2365, 2.3% vs. 33/2366, 1.4%) compared to placebo. The incidence of fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was similar between groups (17 atorvastatin calcium vs. 18 placebo). The incidence of non-fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span> was significantly greater in the atorvastatin group (38 non-fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>) as compared to the placebo group (16 non-fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>). Subjects who entered the study with a <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> appeared to be at increased risk for <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> [7 (16%) atorvastatin calcium vs. 2 (4%) placebo]. </p>
<p>There were no significant differences between the treatment groups for all-cause mortality: 216 (9.1%) in the atorvastatin calcium 80 mg/day group vs. 211 (8.9%) in the placebo group. The proportions of subjects who experienced cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were numerically smaller in the atorvastatin calcium 80 mg group (3.3%) than in the placebo group (4.1%). The proportions of subjects who experienced non-cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were numerically larger in the atorvastatin calcium 80 mg group (5.0%) than in the placebo group (4.0%). </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a65181ac-e482-4536-80c1-a1f762db7509"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">6.2 Postmarketing Experience</span></h2>
<p class="First">The following adverse reactions have been identified during postapproval use of atorvastatin calcium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<p>Adverse reactions associated with atorvastatin calcium therapy reported since market introduction, that are not listed above, regardless of causality assessment, include the following: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous rashes</span> (including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>), <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. </p>
<p>There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with statin use [see <span class="Bold">Warnings and Precautions </span><span class="Bold"><a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a></span>]</p>
<p>There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> (e.g., <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">forgetfulness</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_418e7c53-7dab-418a-8e5c-0ec19a51b670"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold">6.3 Pediatric Patients (ages 10-17 years)</span></h2>
<p class="First">In a 26-week controlled study in boys and postmenarchal girls (n=140, 31% female; 92% Caucasians, 1.6% Blacks, 1.6% Asians, 4.8% other), the safety and tolerability profile of atorvastatin calcium 10 to 20 mg daily was generally similar to that of placebo [see <span class="Bold">Clinical Studies <a href="#LINK_3b4bc8a1-e0ab-48b2-9046-39a9845c690a">(14.6)</a></span> and<span class="Bold"> Use in Special Populations, Pediatric Use <a href="#LINK_0ce6d8de-819a-42ef-9aad-a871cf824b58">(8.4)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_ceceaf58-f6de-47d1-9525-cd708857e93e"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">7 DRUG INTERACTIONS</span></h1>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see <span class="Bold">Warnings and Precautions, Skeletal Muscle <a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a></span> and <span class="Bold">Clinical Pharmacology <a href="#LINK_8bcc8dce-4b63-48eb-8eb9-cbec4e0650c0">(12.3)</a></span>]. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4e6184f8-ecdb-4123-8bae-4b32777b58eb"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">7.1 Strong Inhibitors of CYP 3A4</span></h2>
<p class="First">Atorvastatin calcium is metabolized by cytochrome P450 3A4. Concomitant administration of atorvastatin calcium with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin. The extent of interaction and potentiation of effects depend on the variability of effect on CYP 3A4. </p>
<p>Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin calcium 80 mg with clarithromycin (500 mg twice daily) compared to that of atorvastatin calcium alone [see <span class="Bold">Clinical Pharmacology <a href="#LINK_8bcc8dce-4b63-48eb-8eb9-cbec4e0650c0">(12.3)</a></span>]. Therefore, in patients taking clarithromycin, caution should be used when the atorvastatin calcium dose exceeds 20 mg [see <span class="Bold">Warnings and Precautions, Skeletal Muscle <a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a> </span>and<span class="Bold"> Dosage and Administration <a href="#LINK_cbab7c5b-7cd5-4809-8dd1-edffb204f98f">(2.6)</a></span>]. </p>
<p>Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin calcium with several combinations of HIV protease inhibitors, as well as with the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor telaprevir, compared to that of atorvastatin calcium alone [see <span class="Bold">Clinical Pharmacology </span><span class="Bold"><a href="#LINK_8bcc8dce-4b63-48eb-8eb9-cbec4e0650c0">(12.3)</a></span>]. Therefore, in patients taking the HIV protease inhibitor tipranavir plus ritonavir, or the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor telaprevir, concomitant use of atorvastatin calcium should be avoided. In patients taking the HIV protease inhibitor lopinavir plus ritonavir, caution should be used when prescribing atorvastatin calcium and the lowest dose necessary should be used. In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of atorvastatin calcium should not exceed 20 mg and should be used <span class="Bold">with caution </span>[see <span class="Bold">Warnings and Precautions, Skeletal Muscle <a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a></span> and<span class="Bold"> Dosage and Administration <a href="#LINK_cbab7c5b-7cd5-4809-8dd1-edffb204f98f">(2.6)</a></span>]. </p>
<p>In patients taking the HIV protease inhibitor nelfinavir or the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitor boceprevir, the dose of atorvastatin should not exceed 40 mg and close clinical monitoring is recommended.</p>
<p>Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin calcium 40 mg and itraconazole 200 mg [see <span class="Bold">Clinical Pharmacology (<a href="#LINK_8bcc8dce-4b63-48eb-8eb9-cbec4e0650c0">12.3)</a></span>]. Therefore, in patients taking itraconazole, caution should be used when the atorvastatin calcium dose exceeds 20 mg [see <span class="Bold">Warnings and Precautions, Skeletal Muscle <a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a> </span>and<span class="Bold"> Dosage and Administration <a href="#LINK_cbab7c5b-7cd5-4809-8dd1-edffb204f98f">(2.6)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_09cfd33a-e3bd-4ea3-97bc-1f793c6b182e"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">7.2 Grapefruit Juice</span></h2>
<p class="First">Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (&gt;1.2 liters per day). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a62c3337-b5e1-466c-821f-d1a07e1ab8da"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold">7.3 Cyclosporine</span></h2>
<p class="First">Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin calcium 10 mg and cyclosporine 5.2 mg/kg/day compared to that of atorvastatin calcium alone [see <span class="Bold">Clinical Pharmacology <a href="#LINK_8bcc8dce-4b63-48eb-8eb9-cbec4e0650c0">(12.3)</a></span>]. The co-administration of atorvastatin calcium with cyclosporine should be avoided [see <span class="Bold">Warnings and Precautions, Skeletal Muscle <a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7cff09a6-6418-407c-8f98-d5ff94190f8d"></a><a name="section-7.4"></a><p></p>
<h2><span class="Bold">7.4 Gemfibrozil</span></h2>
<p class="First">Due to an increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> when HMG-CoA reductase inhibitors are co-administered with gemfibrozil, concomitant administration of atorvastatin calcium with gemfibrozil should be avoided [see <span class="Bold">Warnings and Precautions </span><span class="Bold"><a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6322aacf-8474-4606-beac-70f92175cdb5"></a><a name="section-7.5"></a><p></p>
<h2><span class="Bold">7.5 Other Fibrates</span></h2>
<p class="First">Because it is known that the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, atorvastatin calcium should be administered with caution when used concomitantly with other fibrates [see <span class="Bold">Warnings and Precautions </span><span class="Bold"><a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a42d7471-6aad-4ada-b2ec-c3d384a2e9da"></a><a name="section-7.6"></a><p></p>
<h2><span class="Bold">7.6 Niacin</span></h2>
<p class="First">The risk of skeletal muscle effects may be enhanced when atorvastatin calcium is used in combination with niacin; a reduction in atorvastatin calcium dosage should be considered in this setting [see <span class="Bold">Warnings and Precautions </span><span class="Bold"><a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0ad6d71c-8b58-4c2e-963d-533dd2ce0232"></a><a name="section-7.7"></a><p></p>
<h2><span class="Bold">7.7 Rifampin or other Inducers of Cytochrome P450 3A4</span></h2>
<p class="First">Concomitant administration of atorvastatin calcium with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin calcium with rifampin is recommended, as delayed administration of atorvastatin calcium after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_481ca0f3-9c62-4ad2-9008-2e7d77b36bf4"></a><a name="section-7.8"></a><p></p>
<h2><span class="Bold">7.8 Digoxin</span></h2>
<p class="First">When multiple doses of atorvastatin calcium and digoxin were co-administered, steady state plasma digoxin concentrations increased by approximately 20%. Patients taking digoxin should be monitored appropriately. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2d888ae6-21c8-4552-ab39-9b64e3dc34ca"></a><a name="section-7.9"></a><p></p>
<h2><span class="Bold">7.9 Oral Contraceptives</span></h2>
<p class="First">Co-administration of atorvastatin calcium and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see <span class="Bold">Clinical Pharmacology <a href="#LINK_8bcc8dce-4b63-48eb-8eb9-cbec4e0650c0">(12.3)</a></span>]. These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin calcium. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a10a6bf2-35ba-4711-98f0-2ede7ab13750"></a><a name="section-7.10"></a><p></p>
<h2><span class="Bold">7.10 Warfarin</span></h2>
<p class="First">Atorvastatin calcium had no clinically significant effect on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time when administered to patients receiving chronic warfarin treatment. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_edb652a0-9074-4d3d-9045-6f9d2e387a74"></a><a name="section-7.11"></a><p></p>
<h2><span class="Bold">7.11 Colchicine</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_180c1733-d375-4e64-b5e4-e0f33ce7d8de"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">8 USE IN SPECIFIC POPULATIONS</span></h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_f91ec11a-a06f-48c3-94cd-df0112db0c86"></a><a name="section-8.1"></a><p></p>
<h2><span class="Bold">8.1 Pregnancy</span></h2>
<p class="First"><span class="Bold">Pregnancy Category X </span></p>
<p>Atorvastatin calcium is contraindicated in women who are or may become pregnant. Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>. Lipid lowering drugs offer no benefit during pregnancy because <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> derivatives are needed for normal fetal development. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> therapy. </p>
<p>There are no adequate and well-controlled studies of atorvastatin use during pregnancy. There have been rare reports of congenital anomalies following intrauterine exposure to statins. In a review of about 100 prospectively followed pregnancies in women exposed to other statins, the incidences of congenital anomalies, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>, and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>/<span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> did not exceed the rate expected in the general population. However, this study was only able to exclude a three-to-four-fold increased risk of congenital anomalies over background incidence. In 89% of these cases, drug treatment started before pregnancy and stopped during the first trimester when pregnancy was identified. </p>
<p>Atorvastatin crosses the rat placenta and reaches a level in fetal liver equivalent to that of maternal plasma. Atorvastatin was not teratogenic in rats at doses up to 300 mg/kg/day or in rabbits at doses up to 100 mg/kg/day. These doses resulted in multiples of about 30 times (rat) or 20 times (rabbit) the human exposure based on surface area (mg/m<span class="Sup">2</span>) [see <span class="Bold">Contraindications, Pregnancy <a href="#LINK_9b857776-e7f6-4b22-9ff6-813352f0c37b">(4.3)</a></span>]. </p>
<p>In a study in rats given 20, 100, or 225 mg/kg/day, from gestation day 7 through to lactation day 21 (weaning), there was decreased pup survival at birth, neonate, weaning, and maturity in pups of mothers dosed with 225 mg/kg/day. Body weight was decreased on days 4 and 21 in pups of mothers dosed at 100 mg/kg/day; pup body weight was decreased at birth and at days 4, 21, and 91 at 225 mg/kg/day. Pup development was delayed (rotorod performance at 100 mg/kg/day and acoustic startle at 225 mg/kg/day; pinnae detachment and eye-opening at 225 mg/kg/day). These doses correspond to 6 times (100 mg/kg) and 22 times (225 mg/kg) the human AUC at  80 mg/day. </p>
<p>Statins may cause fetal harm when administered to a pregnant woman. Atorvastatin calcium should be administered to women of childbearing potential only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the woman becomes pregnant while taking atorvastatin calcium, it should be discontinued immediately and the patient advised again as to the potential hazards to the fetus and the lack of known clinical benefit with continued use during pregnancy. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_119b5fde-8f4a-45da-ac72-1a98d05dc3fb"></a><a name="section-8.2"></a><p></p>
<h2><span class="Bold">8.3 Nursing Mothers</span></h2>
<p class="First">It is not known whether atorvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk. Nursing rat pups had plasma and liver drug levels of 50% and 40%, respectively, of that in their mother’s milk. Animal breast milk drug levels may not accurately reflect human breast milk levels. Because another drug in this class passes into human milk and because statins have a potential to cause serious adverse reactions in nursing infants, women requiring atorvastatin calcium treatment should be advised not to nurse their infants [see <span class="Bold">Contraindications <a href="#LINK_11804937-b221-4d89-8f10-da587cc69a1d">(4)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6067d55a-bca9-4dfa-bf14-13d4baeb2587"></a><a name="section-8.3"></a><p></p>
<h2><span class="Bold">8.4 Pediatric Use</span></h2>
<p class="First">Safety and effectiveness in patients 10-17 years of age with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> have been evaluated in a controlled clinical trial of 6 months’ duration in adolescent boys and postmenarchal girls. Patients treated with atorvastatin calcium had an adverse experience profile generally similar to that of patients treated with placebo. The most common adverse experiences observed in both groups, regardless of causality assessment, were <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. <span class="Bold">Doses greater than 20 mg have not been studied in this patient population. </span>In this limited controlled study, there was no significant effect on growth or sexual maturation in boys or on menstrual cycle length in girls [see <span class="Bold">Clinical Studies <a href="#LINK_3b4bc8a1-e0ab-48b2-9046-39a9845c690a">(14.6)</a>; Adverse Reactions, Pediatric Patients (ages 10-17 years) <a href="#LINK_fc75e3f4-8dc3-41e9-8da5-c0c0bcaad392">(6.3)</a>; </span>and<span class="Bold"> Dosage and Administration, <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients (10-17 years of age) <a href="#LINK_d4e25197-9325-4d3b-bcb8-737acc0b22a8">(2.2)</a></span>]. Adolescent females should be counseled on appropriate contraceptive methods while on atorvastatin calcium therapy [see <span class="Bold">Contraindications, Pregnancy <a href="#LINK_9b857776-e7f6-4b22-9ff6-813352f0c37b">(4.3</a>) </span>and<span class="Bold"> Use in Specific Populations, Pregnancy <a href="#LINK_353490d3-150f-4be6-8415-1599762af63a">(8.1)</a></span>]. <span class="Bold">Atorvastatin calcium has not been studied in controlled clinical trials involving pre-pubertal patients or patients younger than 10 years of age. </span></p>
<p>Clinical efficacy with doses up to 80 mg/day for 1 year have been evaluated in an uncontrolled study of patients with homozygous FH including 8 pediatric patients [see <span class="Bold">Clinical Studies, <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> <a href="#LINK_a6f07c8f-48b0-4666-930f-b9f2a47de984">(14.5)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_0009d515-86b4-4535-a1f2-75ba661d05ca"></a><a name="section-8.4"></a><p></p>
<h2><span class="Bold">8.5 Geriatric Use</span></h2>
<p class="First">Of the 39,828 patients who received atorvastatin calcium in clinical studies, 15,813 (40%) were ≥65 years old and 2,800 (7%) were ≥75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Since advanced age (≥65 years) is a predisposing factor for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, atorvastatin calcium should be prescribed with caution in the elderly. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_12abff4c-ec15-4980-a6a4-bdfe65b46c7c"></a><a name="section-8.5"></a><p></p>
<h2><span class="Bold">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h2>
<p class="First">Atorvastatin calcium is contraindicated in patients with active liver disease which may include unexplained persistent elevations in hepatic transaminase levels [see <span class="Bold">Contraindications <a href="#LINK_11804937-b221-4d89-8f10-da587cc69a1d">(4)</a> </span>and <span class="Bold">Pharmacokinetics<a href="#LINK_8bcc8dce-4b63-48eb-8eb9-cbec4e0650c0"> (12.3)</a></span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_38bb49ec-b4cd-4878-8362-0898f7923cb9"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">10 OVERDOSAGE</span></h1>
<p class="First">There is no specific treatment for atorvastatin calcium overdosage. In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the patient should be treated symptomatically, and supportive measures instituted as required. Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin calcium clearance.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_cbbbc57e-d221-4303-939b-f6428af94618"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">11 DESCRIPTION</span></h1>
<p class="First">Atorvastatin calcium is a synthetic lipid-lowering agent. Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> biosynthesis. </p>
<p>Atorvastatin calcium is [R-(R*, R*)]-2-(4-fluorophenyl)-ß, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1). The molecular formula of atorvastatin calcium is C<span class="Sub">66</span>H<span class="Sub">68</span>CaF<span class="Sub">2</span>N<span class="Sub">4</span>O<span class="Sub">10 </span>and its molecular weight is 1155.36.  Its structural formula is: </p>
<div class="Figure"><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8f71bea6-2fd0-44ae-afd9-727d365293a0&amp;name=atorvastatin-calcium-tablets---80mg-1.jpg"></div>
<p>Atorvastatin calcium is a white to off-white colored powder free from visible extraneous matter. Atorvastatin calcium is soluble in dimethyl sulphoxide, slightly soluble in alcohol, very slightly soluble in water, in pH 7.4 phosphate buffer and in acetonitrile and practically insoluble in aqueous solutions of pH 4 and below.</p>
<p>Atorvastatin calcium tablets for oral administration contain 80 mg atorvastatin and the following inactive ingredients: Basic butylated methacrylate copolymer, crospovidone, hydroxy propyl cellulose, lactose monohydrate, magnesium stearate, methanol, microcrystalline cellulose, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and sodium lauryl sulphate. The tablet coating contains lecithin, polyvinyl alcohol, talc, titanium dioxide, and xanthan gum.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_307b60a8-076d-4a4b-ba25-538ba9f33592"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">12 CLINICAL PHARMACOLOGY</span></h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_4765dda1-ed3e-4b47-9ae1-29533b94f640"></a><a name="section-11.1"></a><p></p>
<h2><span class="Bold">12.1 Mechanism of Action</span></h2>
<p class="First">Atorvastatin calcium is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> and triglycerides circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), IDL (intermediate-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides (TG) and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily through the high-affinity LDL receptor. Clinical and pathologic studies show that elevated plasma levels of total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (total-C), LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C), and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B (<span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>) promote human <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> and are risk factors for developing cardiovascular disease, while increased levels of HDL-C are associated with a decreased cardiovascular risk. </p>
<p>In animal models, atorvastatin calcium lowers plasma <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and lipoprotein levels by inhibiting HMG-CoA reductase and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin calcium also reduces LDL production and the number of LDL particles. Atorvastatin calcium reduces LDL-C in some patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span> (FH), a population that rarely responds to other lipid-lowering medication(s). </p>
<p>A variety of clinical studies have demonstrated that elevated levels of total-C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span> (a membrane complex for LDL-C) promote human <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. Similarly, decreased levels of HDL-C (and its transport complex, apo A) are associated with the development of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C, and inversely with the level of HDL-C. </p>
<p>Atorvastatin calcium reduces total-C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span> in patients with homozygous and heterozygous FH, nonfamilial forms of <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. Atorvastatin calcium also reduces VLDL-C and TG and produces variable increases in HDL-C and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> A-1. Atorvastatin calcium reduces total-C, LDL-C, VLDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, TG, and non-HDL-C, and increases HDL-C in patients with isolated <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>. Atorvastatin calcium reduces intermediate density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (IDL-C) in patients with dysbetalipoproteinemia.</p>
<p>Like LDL, <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-enriched triglyceride-rich lipoproteins, including VLDL, intermediate density lipoprotein (IDL), and remnants, can also promote <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. Elevated plasma triglycerides are frequently found in a triad with low HDL-C levels and small LDL particles, as well as in association with non-lipid metabolic risk factors for coronary heart disease. As such, total plasma TG has not consistently been shown to be an independent risk factor for CHD. Furthermore, the independent effect of raising HDL or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_6c4d3f1e-7ea3-4660-88b6-ba4a4b02fe69"></a><a name="section-11.2"></a><p></p>
<h2><span class="Bold">12.2 Pharmacodynamics</span></h2>
<p class="First">Atorvastatin calcium, as well as some of its metabolites, are pharmacologically active in humans. The liver is the primary site of action and the principal site of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and LDL clearance. Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response [see <span class="Bold">Dosage and Administration <a href="#LINK_94aa19c6-8be5-41f3-a4f4-79fa79514165">(2)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_da3ea0cc-e62b-4b18-a352-21dc8fc257b5"></a><a name="section-11.3"></a><p></p>
<h2><span class="Bold">12.3 Pharmacokinetics</span></h2>
<p class="First">Absorption: Atorvastatin calcium is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin calcium dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the rate and extent of drug absorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC, LDL-C reduction is similar whether atorvastatin calcium is given with or without food. Plasma atorvastatin calcium concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration [see <span class="Bold">Dosage and Administration <a href="#LINK_94aa19c6-8be5-41f3-a4f4-79fa79514165">(2)</a></span>]. </p>
<p>Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters. Atorvastatin calcium is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, atorvastatin calcium is likely to be secreted in human milk [see <span class="Bold">Contraindications, Nursing Mothers <a href="#LINK_a9202810-102e-43b9-88f3-a3213eb5dd44">(4.4)</a></span> and<span class="Bold"> Use in Specific Populations, Nursing Mothers <a href="#LINK_3eea926f-fc0e-4350-895d-0d1bdf8c401b">(8.3</a>)</span>]. </p>
<p>Metabolism: Atorvastatin calcium is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. <span class="Italics">In vitro</span> inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin calcium. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. <span class="Italics">In vitro</span> studies suggest the importance of atorvastatin calcium metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin calcium in humans following co-administration with erythromycin, a known inhibitor of this isozyme [see <span class="Bold">Drug Interactions <a href="#LINK_5eb958ca-18ec-4235-9467-6ab480ff7235">(7.1)</a></span>]. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation. </p>
<p>Excretion: Atorvastatin calcium and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin calcium in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of atorvastatin calcium is recovered in urine following oral administration. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_043137bf-0d57-4e7e-bb14-a4351fc27ac0"></a><a name="section-11.3.1"></a><p></p>
<h3><span class="Bold">Specific Populations</span></h3>
<p class="First">Geriatric: Plasma concentrations of atorvastatin calcium are higher (approximately 40% for Cmax and 30% for AUC) in healthy elderly subjects (age ≥65 years) than in young adults. Clinical data suggest a greater degree of LDL-lowering at any dose of drug in the elderly patient population compared to younger adults [see <span class="Bold">Use in Specific Populations, Geriatric Use <a href="#LINK_b069e87b-d6db-43c0-a404-51b8da24524a">(8.5)</a></span>]. </p>
<p>Pediatric: Pharmacokinetic data in the pediatric population are not available. </p>
<p>Gender<span class="Bold">: </span>Plasma concentrations of atorvastatin calcium in women differ from those in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with atorvastatin calcium between men and women. </p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal disease</span> has no influence on the plasma concentrations or LDL-C reduction of atorvastatin calcium; thus, dose adjustment in patients with renal dysfunction is not necessary [see <span class="Bold">Dosage and Administration, Dosage in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> <a href="#LINK_e1e96e17-e57b-4f9e-8183-b3130a45f7b3">(2.5)</a>, Warnings and Precautions, Skeletal Muscle <a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a></span>]. </p>
<p>Hemodialysis: While studies have not been conducted in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, hemodialysis is not expected to significantly enhance clearance of atorvastatin calcium since the drug is extensively bound to plasma proteins. </p>
<p><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: In patients with chronic <span class="product-label-link" type="condition" conceptid="201612" conceptname="Alcoholic liver damage">alcoholic liver disease</span>, plasma concentrations of atorvastatin calcium are markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease [see <span class="Bold">Contraindications <a href="#LINK_11804937-b221-4d89-8f10-da587cc69a1d">(4.1)</a></span>].</p>
<p><span class="Bold">TABLE 3. Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin</span></p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">Co-administered drug and dosing regimen</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"> <span class="Bold">Atorvastatin</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  </td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">Dose (mg)</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Change in AUC<span class="Sup">&amp;</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Change in Cmax<span class="Sup">&amp;</span></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Cyclosporine 5.2 mg/kg/day, stable dose </td>
<td class="Botrule Lrule Rrule Toprule"> 10 mg QD for 28 days </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 8.7 fold </td>
<td class="Botrule Lrule Rrule Toprule"> ↑10.7 fold </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days</td>
<td class="Botrule Lrule Rrule Toprule"> 10 mg, SD</td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 9.4 fold</td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 8.6 fold</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Telaprevir 750 mg q8h, 10 days</td>
<td class="Botrule Lrule Rrule Toprule"> 20 mg, SD</td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 7.88 fold</td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 10.6 fold</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#, ‡</span>Saquinavir 400 mg BID/ ritonavir 400mg BID, 15 days</td>
<td class="Botrule Lrule Rrule Toprule"> 40 mg QD for 4 days</td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 3.9 fold</td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 4.3 fold</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Clarithromycin 500 mg BID, 9 days </td>
<td class="Botrule Lrule Rrule Toprule"> 80 mg QD for 8 days </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 4.4 fold </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 5.4 fold </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days</td>
<td class="Botrule Lrule Rrule Toprule"> 10 mg QD for 4 days</td>
<td class="Botrule Lrule Rrule Toprule"> ↑3.4 fold </td>
<td class="Botrule Lrule Rrule Toprule"> ↑2.25 fold </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Itraconazole 200 mg QD, 4 days </td>
<td class="Botrule Lrule Rrule Toprule"> 40 mg SD </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 3.3 fold </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 20% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days</td>
<td class="Botrule Lrule Rrule Toprule"> 10 mg QD for 4 days</td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 2.53 fold </td>
<td class="Botrule Lrule Rrule Toprule"> ↑2.84 fold </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Fosamprenavir 1400 mg BID, 14 days</td>
<td class="Botrule Lrule Rrule Toprule"> 10 mg QD for 4 days</td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 2.3 fold </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 4.04 fold </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Nelfinavir 1250 mg BID, 14 days</td>
<td class="Botrule Lrule Rrule Toprule"> 10 mg QD for 28 days</td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 74%</td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 2.2 fold</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Grapefruit Juice, 240 mL QD * </td>
<td class="Botrule Lrule Rrule Toprule"> 40 mg, SD </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 37% </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 16% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Diltiazem 240 mg QD, 28 days </td>
<td class="Botrule Lrule Rrule Toprule"> 40 mg, SD </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 51% </td>
<td class="Botrule Lrule Rrule Toprule"> No change </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Erythromycin 500 mg QID, 7 days </td>
<td class="Botrule Lrule Rrule Toprule"> 10 mg, SD </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 33% </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 38% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Amlodipine 10 mg, single dose </td>
<td class="Botrule Lrule Rrule Toprule"> 80 mg, SD </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 15% </td>
<td class="Botrule Lrule Rrule Toprule"> ↓ 12 % </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Cimetidine 300 mg QID, 2 weeks </td>
<td class="Botrule Lrule Rrule Toprule"> 10 mg QD for 2 weeks </td>
<td class="Botrule Lrule Rrule Toprule"> ↓ Less than 1% </td>
<td class="Botrule Lrule Rrule Toprule"> ↓ 11% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Colestipol 10 mg BID, 28 weeks </td>
<td class="Botrule Lrule Rrule Toprule"> 40 mg QD for 28 weeks </td>
<td class="Botrule Lrule Rrule Toprule"> Not determined </td>
<td class="Botrule Lrule Rrule Toprule"> ↓ 26%** </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Maalox TC® 30 mL QD, 17 days </td>
<td class="Botrule Lrule Rrule Toprule"> 10 mg QD for 15 days </td>
<td class="Botrule Lrule Rrule Toprule"> ↓ 33% </td>
<td class="Botrule Lrule Rrule Toprule"> ↓ 34% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Efavirenz 600 mg QD, 14 days </td>
<td class="Botrule Lrule Rrule Toprule"> 10 mg for 3 days </td>
<td class="Botrule Lrule Rrule Toprule"> ↓ 41% </td>
<td class="Botrule Lrule Rrule Toprule"> ↓ 1% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Rifampin 600 mg QD, 7 days (co-administered) <span class="Sup">† </span>
</td>
<td class="Botrule Lrule Rrule Toprule"> 40 mg SD </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 30% </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 2.7 fold </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Rifampin 600 mg QD, 5 days (doses separated) <span class="Sup">† </span>
</td>
<td class="Botrule Lrule Rrule Toprule"> 40 mg SD </td>
<td class="Botrule Lrule Rrule Toprule"> ↓ 80% </td>
<td class="Botrule Lrule Rrule Toprule"> ↓ 40% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Gemfibrozil 600mg BID, 7 days </td>
<td class="Botrule Lrule Rrule Toprule"> 40mg SD </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 35% </td>
<td class="Botrule Lrule Rrule Toprule"> ↓ Less than 1% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span>Fenofibrate 160mg QD, 7 days </td>
<td class="Botrule Lrule Rrule Toprule"> 40mg SD </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 3% </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 2% </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"> Boceprevir 800 mg TID, 7 days</td>
<td class="Botrule Lrule Rrule Toprule"> 40 mg SD</td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 2.30 fold</td>
<td class="Botrule Lrule Rrule Toprule"> ↑2.66 fold</td>
</tr>
</tbody>
</table>
<p><span class="Sup">&amp;         </span>Data given as x-fold change represent a simple ratio between co-administration and atorvastatin alone (i.e., 1-fold = no change). Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change). </p>
<p><span class="Sup">#   </span>See Sections 5.1 and 7 for clinical significance.</p>
<p>*   Greater increases in AUC (up to 2.5 fold) and/or Cmax (up to 71%) have been reported with excessive grapefruit consumption (≥ 750 mL - 1.2 liters per day). </p>
<p>**  Single sample taken 8-16 h post dose. </p>
<p><span class="Sup">†    </span>Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.</p>
<p><span class="Sup">‡</span>       The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, caution should be applied and the lowest dose necessary should be used.</p>
<p><span class="Bold">TABLE 4. Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs</span></p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">Atorvastatin</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"> <span class="Bold">Co-administered drug and dosing regimen</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  </td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">Drug/Dose (mg)</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Change in AUC</span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">Change in Cmax</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 80 mg QD for 15 days </td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Antipyrine, 600 mg SD </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 3% </td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> ↓ 11% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 80 mg QD for 14 days </td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Sup">#</span> Digoxin 0.25 mg QD, 20 days </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 15% </td>
<td class="Botrule Lrule Rrule Toprule"> ↑ 20 % </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 40 mg QD for 22 days </td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Oral contraceptive QD, 2 months <br>- norethindrone 1mg <br>- ethinyl estradiol 35μg </td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  <br>↑ 28% <br>↑ 19%</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  <br>↑ 23% <br>↑ 30%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 10 mg, SD</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> No change</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> No change</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 10 mg QD for 4 days</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Fosamprenavir 1400 mg BID, 14 days</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> ↓ 27%</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> ↓ 18%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"> 10 mg QD for 4 days</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> No change</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> No change</td>
</tr>
</tbody>
</table>
<p># See Section 7 for clinical significance.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_3a5ea9c5-67c0-4fbf-b36f-a6f9cf855525"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">13 NONCLINICAL TOXICOLOGY</span></h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_476e158a-60cd-4c92-8337-ccd468476011"></a><a name="section-12.1"></a><p></p>
<h2><span class="Bold">13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</span></h2>
<p class="First">In a 2-year carcinogenicity study in rats at dose levels of 10, 30, and 100 mg/kg/day, 2 rare tumors were found in muscle in high-dose females: in one, there was a <span class="product-label-link" type="condition" conceptid="4116201" conceptname="Rhabdomyosarcoma">rhabdomyosarcoma</span> and, in another, there was a <span class="product-label-link" type="condition" conceptid="4202374" conceptname="Fibrosarcoma">fibrosarcoma</span>. This dose represents a plasma AUC (0-24) value of approximately 16 times the mean human plasma drug exposure after an 80 mg oral dose. </p>
<p>A 2-year carcinogenicity study in mice given 100, 200, or 400 mg/kg/day resulted in a significant increase in liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in high-dose males and <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">liver carcinomas</span> in high-dose females. These findings occurred at plasma AUC (0–24) values of approximately 6 times the mean human plasma drug exposure after an 80 mg oral dose. </p>
<p><span class="Italics">In vitro,</span> atorvastatin was not mutagenic or clastogenic in the following tests with and without metabolic activation: the Ames test with <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium and Escherichia coli, the HGPRT forward mutation assay in Chinese hamster lung cells, and the chromosomal aberration assay in Chinese hamster lung cells. Atorvastatin was negative in the <span class="Italics">in vivo </span>mouse micronucleus test. </p>
<p>Studies in rats performed at doses up to 175 mg/kg (15 times the human exposure) produced no changes in fertility. There was <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> and <span class="product-label-link" type="condition" conceptid="40492473" conceptname="Aspermia">aspermia</span> in the epididymis of 2 of 10 rats treated with 100 mg/kg/day of atorvastatin for 3 months (16 times the human AUC at the 80 mg dose); testis weights were significantly lower at 30 and 100 mg/kg and epididymal weight was lower at 100 mg/kg. Male rats given 100 mg/kg/day for 11 weeks prior to mating had decreased sperm motility, spermatid head concentration, and increased abnormal sperm. Atorvastatin caused no adverse effects on semen parameters, or reproductive organ histopathology in dogs given doses of 10, 40, or 120 mg/kg for two years. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_5bda0c1a-4bb8-4c7c-8290-5f1b8efe44db"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">14 CLINICAL STUDIES</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e55e2628-454a-4303-9915-e4adcda29ac4"></a><a name="section-13.1"></a><p></p>
<h2><span class="Bold">14.1 Prevention of Cardiovascular Disease </span></h2>
<p class="First">In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the effect of atorvastatin calcium on fatal and non-fatal coronary heart disease was assessed in 10,305 hypertensive patients 40–80 years of age (mean of 63 years), without a previous <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and with TC levels ≤251 mg/dL (6.5 mmol/L). Additionally, all patients had at least 3 of the following cardiovascular risk factors: male gender (81.1%), age &gt;55 years (84.5%), smoking (33.2%), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (24.3%), history of CHD in a first-degree relative (26%), TC:HDL &gt;6 (14.3%), <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> (5.1%), <span class="product-label-link" type="condition" conceptid="4184746" conceptname="Left ventricular hypertrophy">left ventricular hypertrophy</span> (14.4%), prior cerebrovascular event (9.8%), specific ECG abnormality (14.3%), <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>/<span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span> (62.4%). In this double-blind, placebo-controlled study, patients were treated with anti-hypertensive therapy (Goal BP &lt;140/90 mm Hg for non-diabetic patients; &lt;130/80 mm Hg for diabetic patients) and allocated to either atorvastatin calcium 10 mg daily (n=5168) or placebo (n=5137), using a covariate adaptive method which took into account the distribution of nine baseline characteristics of patients already enrolled and minimized the imbalance of those characteristics across the groups. Patients were followed for a median duration of 3.3 years. </p>
<p>The effect of 10 mg/day of atorvastatin calcium on lipid levels was similar to that seen in previous clinical trials. </p>
<p>Atorvastatin calcium significantly reduced the rate of coronary events [either fatal coronary heart disease (46 events in the placebo group vs. 40 events in the atorvastatin calcium group) or non-fatal MI (108 events in the placebo group vs. 60 events in the atorvastatin calcium group)] with a relative risk reduction of 36% [(based on incidences of 1.9% for atorvastatin calcium vs. 3.0% for placebo), p=0.0005 (see Figure 1)]. The risk reduction was consistent regardless of age, smoking status, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, or presence of renal dysfunction. The effect of atorvastatin calcium was seen regardless of baseline LDL levels. Due to the small number of events, results for women were inconclusive.</p>
<p><span class="Bold">Figure 1: Effect of Atorvastatin Calcium 10 mg/day on Cumulative Incidence of Non-Fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span> or Coronary Heart Disease <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (in ASCOT-LLA) </span></p>
<div class="Figure"><img alt="figure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8f71bea6-2fd0-44ae-afd9-727d365293a0&amp;name=atorvastatin-calcium-tablets---80mg-2.jpg"></div>
<p>Atorvastatin calcium also significantly decreased the relative risk for revascularization procedures by 42%. Although the reduction of fatal and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> did not reach a pre-defined significance level (p=0.01), a favorable trend was observed with a 26% relative risk reduction (incidences of 1.7% for atorvastatin calcium and 2.3% for placebo). There was no significant difference between the treatment groups for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to cardiovascular causes (p=0.51) or noncardiovascular causes (p=0.17). </p>
<p>In the Collaborative Atorvastatin <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Study (CARDS), the effect of atorvastatin calcium on cardiovascular disease (CVD) endpoints was assessed in 2838 subjects (94% white, 68% male), ages 40–75 with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> based on WHO criteria, without prior history of cardiovascular disease and with LDL ≤ 160 mg/dL and TG ≤ 600 mg/dL. In addition to <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, subjects had 1 or more of the following risk factors: current smoking (23%), <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (80%), <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> (30%), or <span class="product-label-link" type="condition" conceptid="4195061" conceptname="Microalbuminuria">microalbuminuria</span> (9%) or macroalbuminuria (3%). No subjects on hemodialysis were enrolled in the study. In this multicenter, placebo-controlled, double-blind clinical trial, subjects were randomly allocated to either atorvastatin calcium 10 mg daily (1429) or placebo (1411) in a 1:1 ratio and were followed for a median duration of 3.9 years. The primary endpoint was the occurrence of any of the major cardiovascular events: <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, acute CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>, coronary revascularization, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. The primary analysis was the time to first occurrence of the primary endpoint. </p>
<p>Baseline characteristics of subjects were: mean age of 62 years, mean HbA1c 7.7%; median LDL-C 120 mg/dL; median TC 207 mg/dL; median TG 151 mg/dL; median HDL-C 52 mg/dL. </p>
<p>The effect of atorvastatin calcium 10 mg/day on lipid levels was similar to that seen in previous clinical trials. </p>
<p>Atorvastatin calcium significantly reduced the rate of major cardiovascular events (primary endpoint events) (83 events in the atorvastatin calcium group vs. 127 events in the placebo group) with a relative risk reduction of 37%, HR 0.63, 95% CI (0.48, 0.83) (p=0.001) (see  Figure 2). An effect of atorvastatin calcium was seen regardless of age, sex, or baseline lipid levels. </p>
<p>Atorvastatin calcium significantly reduced the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> by 48% (21 events in the atorvastatin calcium group vs. 39 events in the placebo group), HR 0.52, 95% CI (0.31, 0.89) (p=0.016) and reduced the risk of MI by 42% (38 events in the atorvastatin calcium group vs. 64 events in the placebo group), HR 0.58, 95.1% CI (0.39, 0.86) (p=0.007). There was no significant difference between the treatment groups for angina, revascularization procedures, and acute CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p>There were 61 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the atorvastatin calcium group vs. 82 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the placebo group (HR 0.73, p=0.059).</p>
<p><span class="Bold">Figure 2: Effect of Atorvastatin Calcium 10 mg/day on Time to Occurrence of Major Cardiovascular Event (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, acute CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>, coronary revascularization, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>) in CARDS</span></p>
<p><img alt="figure2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8f71bea6-2fd0-44ae-afd9-727d365293a0&amp;name=atorvastatin-calcium-tablets---80mg-3.jpg"> </p>
<p>In the Treating to New Targets Study (TNT), the effect of atorvastatin calcium 80 mg/day vs. atorvastatin calcium 10 mg/day on the reduction in cardiovascular events was assessed in 10,001 subjects (94% white, 81% male, 38% ≥65 years) with clinically evident coronary heart disease who had achieved a target LDL-C level &lt;130 mg/dL after completing an 8-week, open-label, run-in period with atorvastatin calcium 10 mg/day. Subjects were randomly assigned to either 10 mg/day or 80 mg/day of atorvastatin calcium and followed for a median duration of 4.9 years. The primary endpoint was the time-to-first occurrence of any of the following major cardiovascular events (MCVE): <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to CHD, non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and fatal and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. The mean LDL-C, TC, TG, non-HDL, and HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels at 12 weeks were 73, 145, 128, 98, and 47 mg/dL during treatment with 80 mg of atorvastatin calcium and 99, 177, 152, 129, and 48 mg/dL during treatment with 10 mg of atorvastatin calcium. </p>
<p>Treatment with atorvastatin calcium 80 mg/day significantly reduced the rate of MCVE (434 events in the 80 mg/day group vs. 548 events in the 10 mg/day group) with a relative risk reduction of 22%, HR 0.78, 95% CI (0.69, 0.89), p=0.0002 (see Figure 3 and Table 5). The overall risk reduction was consistent regardless of age (&lt;65, ≥65) or gender. </p>
<p><span class="Bold">Figure 3: Effect of Atorvastatin Calcium 80 mg/day vs. 10 mg/day on Time to Occurrence of Major Cardiovascular Events (TNT)</span></p>
<div class="Figure"><img alt="figure3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8f71bea6-2fd0-44ae-afd9-727d365293a0&amp;name=atorvastatin-calcium-tablets---80mg-4.jpg"></div>
<p><span class="Bold">TABLE 5. Overview of Efficacy Results in TNT</span></p>
<table>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">Endpoint</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"> <span class="Bold">Atorvastatin 10 mg</span></p>
<p><span class="Bold">(N=5006)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"> <span class="Bold">Atorvastatin 80 mg</span></p>
<p><span class="Bold">(N=4995)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> <span class="Bold">HR<span class="Sup">a</span> (95%Cl)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">PRIMARY ENDPOINT</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> n</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> n</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> First major cardiovascular endpoint </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 548</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (10.9)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 434</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (8.7)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 0.78 (0.69, 0.89)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">Components of the Primary Endpoint</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 127</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (2.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 101</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (2.0)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 0.80 (0.61, 1.03)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Non-fatal, non-procedure related Ml </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 308</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (6.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 243</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (4.9)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 0.78 (0.66, 0.93)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 26</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (0.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 25</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (0.5)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 0.96 (0.56, 1.67)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> (fatal and non-fatal) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 155</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (3.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 117</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (2.3)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 0.75 (0.59, 0.96)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">SECONDARY ENDPOINTS*</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> First CHF with hospitalization </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 164</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (3.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 122</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (2.4)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 0.74 (0.59, 0.94)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> First PVD endpoint </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 282</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (5.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 275</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (5.5)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 0.97 (0.83, 1.15)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> First CABG or other coronary revascularization procedure<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 904</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (18.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 667</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (13.4)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 0.72 (0.65, 0.80)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> First documented angina endpoint<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 615</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (12.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 545</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (10.9)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 0.88 (0.79, 0.99)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> All-cause mortality </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 282</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (5.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 284</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (5.7)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 1.01 (0.85, 1.19)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">Components of All-Cause Mortality</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 155</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (3.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 126</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (2.5)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 0.81 (0.64, 1.03)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Noncardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 127</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (2.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 158</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (3.2)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 1.25 (0.99, 1.57)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Cancer <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 75</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (1.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 85</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (1.7)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 1.13 (0.83, 1.55)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Other non-CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 43</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (0.9)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 58</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (1.2)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 1.35 (0.91, 2.00)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>, homicide, and other traumatic non-CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (0.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 15</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> (0.3)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> 1.67 (0.73, 3.82)</td>
</tr>
</tbody>
</table>
<p>a      Atorvastatin 80 mg: atorvastatin 10 mg </p>
<p>b      Component of other secondary endpoints </p>
<p>*      Secondary endpoints not included in primary endpoint HR=hazard ratio; CHD=coronary heart disease; CI=confidence interval; MI=<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; CHF=<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>; CV=cardiovascular; PVD=<span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>; CABG=coronary artery bypass graft </p>
<p>Confidence intervals for the Secondary Endpoints were not adjusted for multiple comparisons </p>
<p>Of the events that comprised the primary efficacy endpoint, treatment with atorvastatin calcium 80 mg/day significantly reduced the rate of non-fatal, non-procedure related MI and fatal and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, but not CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> (Table 5). Of the predefined secondary endpoints, treatment with atorvastatin calcium 80 mg/day significantly reduced the rate of coronary revascularization, angina, and hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, but not <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>. The reduction in the rate of CHF with hospitalization was only observed in the 8% of patients with a prior history of CHF. </p>
<p>There was no significant difference between the treatment groups for all-cause mortality (Table 5). The proportions of subjects who experienced cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, including the components of CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, were numerically smaller in the atorvastatin calcium 80 mg group than in the atorvastatin calcium 10 mg treatment group. The proportions of subjects who experienced noncardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were numerically larger in the atorvastatin calcium 80 mg group than in the atorvastatin calcium 10 mg treatment group. </p>
<p>In the Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study (IDEAL), treatment with atorvastatin calcium 80 mg/day was compared to treatment with simvastatin  20–40 mg/day in 8,888 subjects up to 80 years of age with a history of CHD to assess whether reduction in CV risk could be achieved. Patients were mainly male (81%), white (99%) with an average age of 61.7 years, and an average LDL-C of 121.5 mg/dL at randomization; 76% were on statin therapy. In this prospective, randomized, open-label, blinded endpoint (PROBE) trial with no run-in period, subjects were followed for a median duration of 4.8 years. The mean LDL-C, TC, TG, HDL, and non-HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels at Week 12 were 78, 145, 115, 45, and 100 mg/dL during treatment with 80 mg of atorvastatin calcium and 105, 179, 142, 47, and 132 mg/dL during treatment with 20–40 mg of simvastatin. </p>
<p>There was no significant difference between the treatment groups for the primary endpoint, the rate of first major coronary event (fatal CHD, non-fatal MI, and resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>): 411 (9.3%) in the atorvastatin calcium 80 mg/day group vs. 463 (10.4%) in the simvastatin 20–40 mg/day group, HR 0.89, 95% Cl ( 0.78, 1.01), p=0.07.</p>
<p>There were no significant differences between the treatment groups for all-cause mortality: 366 (8.2%) in the atorvastatin calcium 80 mg/day group vs. 374 (8.4%) in the simvastatin 20–40 mg/day group. The proportions of subjects who experienced CV or non-CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were similar for the atorvastatin calcium 80 mg group and the simvastatin 20–40 mg group. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bf557da3-0c45-49c6-b32a-6490f88ae9d0"></a><a name="section-13.2"></a><p></p>
<h2>
<span class="Bold">14.2 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> (</span><span class="Bold"><span class="Italics">Fredrickson</span></span><span class="Bold"> Types IIa and IIb)</span>
</h2>
<p class="First">Atorvastatin calcium reduces total-C, LDL-C, VLDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, and TG, and increases HDL-C in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. Therapeutic response is seen within 2 weeks, and maximum response is usually achieved within 4 weeks and maintained during chronic therapy.</p>
<p>Atorvastatin calcium is effective in a wide variety of patient populations with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, with and without <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, in men and women, and in the elderly. </p>
<p>In two multicenter, placebo-controlled, dose-response studies in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, atorvastatin calcium given as a single dose over 6 weeks, significantly reduced total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, and TG. (Pooled results are provided in Table 6.) </p>
<p><span class="Bold">TABLE 6. Dose Response in Patients With Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Adjusted Mean % Change From Baseline)<span class="Sup">a</span></span></p>
<table>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"> Dose</td>
<td class="Botrule Lrule Toprule" align="center" valign="top"> N</td>
<td class="Botrule Lrule Toprule" align="center" valign="top"> TC</td>
<td class="Botrule Lrule Toprule" align="center" valign="top"> LDL-C</td>
<td class="Botrule Lrule Toprule" align="center" valign="top"> <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"> TG</td>
<td class="Botrule Lrule Toprule" align="center" valign="top"> HDL-C</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> Non-HDLC/ HDL-C</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"> Placebo</td>
<td class="Botrule Rrule" align="center" valign="top"> 21</td>
<td class="Botrule Rrule" align="center" valign="top"> 4</td>
<td class="Botrule Rrule" align="center" valign="top"> 4</td>
<td class="Botrule Rrule" align="center" valign="top"> 3</td>
<td class="Botrule Rrule" align="center" valign="top"> 10</td>
<td class="Botrule Rrule" align="center" valign="top"> -3</td>
<td class="Botrule Rrule" align="center" valign="top"> 7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"> 10</td>
<td class="Botrule Rrule" align="center" valign="top"> 22</td>
<td class="Botrule Rrule" align="center" valign="top"> -29</td>
<td class="Botrule Rrule" align="center" valign="top"> -39</td>
<td class="Botrule Rrule" align="center" valign="top"> -32</td>
<td class="Botrule Rrule" align="center" valign="top"> -19</td>
<td class="Botrule Rrule" align="center" valign="top"> 6</td>
<td class="Botrule Rrule" align="center" valign="top"> -34</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"> 20</td>
<td class="Botrule Rrule" align="center" valign="top"> 20</td>
<td class="Botrule Rrule" align="center" valign="top"> -33</td>
<td class="Botrule Rrule" align="center" valign="top"> -43</td>
<td class="Botrule Rrule" align="center" valign="top"> -35</td>
<td class="Botrule Rrule" align="center" valign="top"> -26</td>
<td class="Botrule Rrule" align="center" valign="top"> 9</td>
<td class="Botrule Rrule" align="center" valign="top"> -41</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"> 40</td>
<td class="Botrule Rrule" align="center" valign="top"> 21</td>
<td class="Botrule Rrule" align="center" valign="top"> -37</td>
<td class="Botrule Rrule" align="center" valign="top"> -50</td>
<td class="Botrule Rrule" align="center" valign="top"> -42</td>
<td class="Botrule Rrule" align="center" valign="top"> -29</td>
<td class="Botrule Rrule" align="center" valign="top"> 6</td>
<td class="Botrule Rrule" align="center" valign="top"> -45</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"> 80</td>
<td class="Botrule Rrule" align="center" valign="top"> 23</td>
<td class="Botrule Rrule" align="center" valign="top"> -45</td>
<td class="Botrule Rrule" align="center" valign="top"> -60</td>
<td class="Botrule Rrule" align="center" valign="top"> -50</td>
<td class="Botrule Rrule" align="center" valign="top"> -37</td>
<td class="Botrule Rrule" align="center" valign="top"> 5</td>
<td class="Botrule Rrule" align="center" valign="top"> -53</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Results are pooled from 2 dose-response studies. </p>
<p>In patients with <span class="Italics">Fredrickson </span>Types IIa and IIb <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipoproteinemia</span> pooled from 24 controlled trials, the median (25th and 75th percentile) percent changes from baseline in HDL-C for atorvastatin calcium 10, 20, 40, and 80 mg were 6.4 (-1.4, 14), 8.7 (0, 17), 7.8 (0, 16), and  5.1 (-2.7, 15), respectively. Additionally, analysis of the pooled data demonstrated consistent and significant decreases in total-C, LDL-C, TG, total-C/HDL-C, and LDL-C/HDL-C.     </p>
<p>In three multicenter, double-blind studies in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, atorvastatin calcium was compared to other statins. After randomization, patients were treated for 16 weeks with either atorvastatin calcium 10 mg per day or a fixed dose of the comparative agent (Table 7).</p>
<p><span class="Bold">TABLE 7. Mean Percentage Change From Baseline at Endpoint (Double-Blind, Randomized, Active-Controlled Trials)</span></p>
<table>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"> Treatment<br>(Daily Dose)</td>
<td class="Botrule Lrule Toprule" align="center" valign="top"> N</td>
<td class="Botrule Lrule Toprule" align="center" valign="top"> Total-C</td>
<td class="Botrule Lrule Toprule" align="center" valign="top"> LDL-C</td>
<td class="Botrule Lrule Toprule" align="center" valign="top"> <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"> TG</td>
<td class="Botrule Lrule Toprule" align="center" valign="top"> HDL-C</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> Non-HDL-C/ HDL-C</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="8" valign="top"><span class="Italics"> Study 1</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Atorvastatin Calcium 10 mg </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 707</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -27<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -36<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -28<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -17<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> +7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -37<span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Lovastatin 20 mg 95% Cl for Diff<span class="Sup">1</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 191</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -19<br>-9.2, -6.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -27<br>-10.7, -7.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -20<br>-10.0, -6.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -6<br>-15.2, -7.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> +7<br>-1.7, 2.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -28<br>-11.1, -7.1</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="8" valign="top"> <span class="Italics">Study 2</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<span class="Italics"> </span>Atorvastatin Calcium 10 mg </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> 222</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> -25<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> -35<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="bottom"> -27<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> -17<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> +6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> -36<span class="Sup">b</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Pravastatin 20 mg 95% Cl for Diff<span class="Sup">1</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 77</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -17<br>-10.8, -6.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -23<br>-14.5, -8.2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -17<br>-13.4, -7.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -9<br>-14.1, -0.7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> +8<br>-4.9, 1.6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -28<br>-11.5, -4.1</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="8" valign="top">
<span class="Italics"> Study </span>3  </td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Atorvastatin Calcium 10 mg </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 132</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -29<span class="Sup">c</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -37<span class="Sup">c</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -34<span class="Sup">c</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -23<span class="Sup">c</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> +7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -39<span class="Sup">c</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"> Simvastatin 10 mg 95% Cl for Diff<span class="Sup">1</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 45</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -24<br>-8.7, -2.7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -30<br>-10.1, -2.6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -30<br>-8.0, -1.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -15<br>-15.1, -0.7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> +7<br>-4.3, 3.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -33<br>-9.6, -1.9</td>
</tr>
</tbody>
</table>
<p><span class="Sup">1</span> A negative value for the 95% Cl for the difference between treatments favors atorvastatin calcium for all except HDL-C, for which a positive value favors atorvastatin calcium. If the range does not include 0, this indicates a statistically significant difference. </p>
<p><span class="Sup">a</span>  Significantly different from lovastatin, ANCOVA, p ≤0.05 </p>
<p><span class="Sup">b</span> Significantly different from pravastatin, ANCOVA, p ≤0.05 </p>
<p><span class="Sup">c</span> Significantly different from simvastatin, ANCOVA, p ≤0.05 </p>
<p>The impact on clinical outcomes of the differences in lipid-altering effects between treatments shown in Table 7 is not known. Table 7 does not contain data comparing the effects of atorvastatin calcium 10 mg and higher doses of lovastatin, pravastatin, and simvastatin. The drugs compared in the studies summarized in the table are not necessarily interchangeable. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_964f17dd-f2e7-4b4c-9239-abb6f1d99a56"></a><a name="section-13.3"></a><p></p>
<h2>
<span class="Bold">14.3 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> (</span><span class="Bold"><span class="Italics">Fredrickson </span></span><span class="Bold">Type IV) </span>
</h2>
<p class="First">The response to atorvastatin calcium in 64 patients with isolated <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> treated across several clinical trials is shown in the table below (Table 8). For the atorvastatin calcium-treated patients, median (min, max) baseline TG level was 565 (267–1502). </p>
<p><span class="Bold">TABLE 8. Combined Patients With Isolated Elevated TG: Median (min, max) Percentage Change From Baseline </span></p>
<table>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">  </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"> Placebo</p>
<p>(N=12)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"> Atorvastatin Calcium 10 mg</p>
<p>(N=37)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"> Atorvastatin Calcium 20 mg</p>
<p>(N=13)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"> Atorvastatin Calcium 80 mg</p>
<p> (N=14)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Triglycerides </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -12.4 (-36.6, 82.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -41.0 (-76.2, 49.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -38.7 (-62.7, 29.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -51.8 (-82.8, 41.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Total-C </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -2.3 (-15.5, 24.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -28.2 (-44.9, -6.8)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -34.9 (-49.6, -15.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -44.4 (-63.5, -3.8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> LDL-C </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 3.6 (-31.3, 31.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -26.5 (-57.7, 9.8)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -30.4 (-53.9, 0.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -40.5 (-60.6, -13.8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> HDL-C </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 3.8 (-18.6, 13.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 13.8 (-9.7, 61.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 11.0 (-3.2, 25.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 7.5 (-10.8, 37.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> VLDL-C </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -1.0 (-31.9, 53.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -48.8 (-85.8, 57.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -44.6 (-62.2, -10.8)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -62.0 (-88.2, 37.6)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"> non-HDL-C </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -2.8 (-17.6, 30.0)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -33.0 (-52.1, -13.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -42.7 (-53.7, -17.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -51.5 (-72.9, -4.3)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_351925c8-6c04-4e08-ae72-12714ccae031"></a><a name="section-13.4"></a><p></p>
<h2><span class="Bold">14.4 Dysbetalipoproteinemia </span></h2>
<p class="First">The results of an open-label crossover study of 16 patients (genotypes: 14 apo E2/E2 and 2 apo E3/E2) with dysbetalipoproteinemia (<span class="Italics">Fredrickson</span> Type III) are shown in the table below (Table 9). </p>
<p><span class="Bold">TABLE 9. Open-Label Crossover Study of 16 Patients With Dysbetalipoproteinemia (</span><span class="Bold"><span class="Italics">Fredrickson </span></span><span class="Bold">Type III) </span></p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule" colspan="2" valign="top">  </td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top">                              Median % Change (min, max)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"> Median (min, max) at</p>
<p> Baseline (mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"> Atorvastatin Calcium</p>
<p> 10 mg</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"> Atorvastatin Calcium</p>
<p> 80 mg</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Total-C </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 442 (225, 1320)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -37 (-85, 17)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -58 (-90, -31)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> Triglycerides </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 678 (273, 5990)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -39 (-92, -8)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -53 (-95, -30)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> IDL-C + VLDL-C </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 215 (111, 613)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -32 (-76, 9)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -63 (-90, -8)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"> non-HDL-C </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 411 (218, 1272)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -43 (-87, -19)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -64 (-92, -36)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e9e6504b-380f-491c-af16-de81485b8322"></a><a name="section-13.5"></a><p></p>
<h2><span class="Bold">14.5 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> </span></h2>
<p class="First">In a study without a concurrent control group, 29 patients ages 6 to 37 years with homozygous FH received maximum daily doses of 20 to 80 mg of atorvastatin calcium. The mean LDL-C reduction in this study was 18%. Twenty-five patients with a reduction in LDL-C had a mean response of 20% (range of 7% to 53%, median of 24%); the remaining 4 patients had 7% to 24% increases in LDL-C. Five of the 29 patients had absent LDL-receptor function. Of these, 2 patients also had a portacaval shunt and had no significant reduction in LDL-C. The remaining 3 receptor-negative patients had a mean LDL-C reduction of 22%. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a370f417-3bde-47ca-93f2-436c66df026d"></a><a name="section-13.6"></a><p></p>
<h2><span class="Bold">14.6 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients </span></h2>
<p class="First">In a double-blind, placebo-controlled study followed by an open-label phase, 187 boys and postmenarchal girls 10-17 years of age (mean age 14.1 years) with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (FH) or severe <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, were randomized to atorvastatin calcium (n=140) or placebo (n=47) for 26 weeks and then all received atorvastatin calcium for 26 weeks. Inclusion in the study required 1) a baseline LDL-C level ≥ 190 mg/dL or 2) a baseline LDL-C level ≥ 160 mg/dL and positive family history of FH or documented premature cardiovascular disease in a first or second-degree relative. The mean baseline LDL-C value was 218.6 mg/dL (range: 138.5–385.0 mg/dL) in the atorvastatin calcium group compared to 230.0 mg/dL (range: 160.0–324.5 mg/dL) in the placebo group. The dosage of atorvastatin calcium (once daily) was 10 mg for the first 4 weeks and uptitrated to 20 mg if the LDL-C level was &gt; 130 mg/dL. The number of atorvastatin calcium-treated patients who required uptitration to 20 mg after Week 4 during the double-blind phase was 78 (55.7%). </p>
<p>Atorvastatin calcium significantly decreased plasma levels of total-C, LDL-C, triglycerides, and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B during the 26-week double-blind phase (see Table 10). </p>
<p><span class="Bold">TABLE 10. Lipid-altering Effects of Atorvastatin Calcium in Adolescent Boys and Girls with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> or Severe <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> (Mean Percentage Change From Baseline at Endpoint in Intention-to-Treat Population) </span></p>
<table>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"> DOSAGE </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> N</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> Total-C</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> LDL-C</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> HDL-C</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> TG</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">Apolipoprotein</span> B</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> Placebo </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 47</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> -1.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> -0.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> -1.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 1.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 0.7</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"> Atorvastatin Calcium </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> 140</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> -31.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> -39.6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> 2.8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> -12.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> -34.0</td>
</tr>
</tbody>
</table>
<p>The mean achieved LDL-C value was 130.7 mg/dL (range: 70.0–242.0 mg/dL) in the atorvastatin calcium group compared to 228.5 mg/dL (range: 152.0–385.0 mg/dL) in the placebo group during the  26-week double-blind phase. </p>
<p>The safety and efficacy of doses above 20 mg have not been studied in controlled trials in children. The long-term efficacy of atorvastatin calcium therapy in childhood to reduce morbidity and mortality in adulthood has not been established. </p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_228ee9b8-98e1-4fe1-83f1-09dcf0914bf7"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">15 REFERENCES</span></h1>
<p class="First"><span class="Sup">1      </span>National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels in Children and Adolescents, Pediatrics.  89(3):495-501. 1992. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_3b6283b5-2b50-4a96-abe3-4d19f08b1522"></a><a name="section-15"></a><p></p>
<h1><span class="Bold">16 HOW SUPPLIED/STORAGE AND HANDLING</span></h1>
<p class="First">Atorvastatin calcium tablets of 80 mg are white to off-white, oval shaped, biconvex, film coated tablets  debossed ‘RDY’ on one side and ‘124’ on other side and are supplied in bottles of 30’s, 60’s, 90’s and 500’s.</p>
<p>Blistercards of 30                                             NDC 0615-7772-39 </p>
<p>Blistercards of 15                                             NDC 0615-7772-05 </p>
<p><span class="Bold">Storage </span></p>
<p>Store atorvastatin calcium tablets at 20° - 25°C (68° - 77°F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_b592c54b-ffbc-425c-bbf1-d559d4c84961"></a><a name="section-16"></a><p></p>
<h1><span class="Bold">17 PATIENT COUNSELING INFORMATION</span></h1>
<p class="First">Patients taking atorvastatin calcium should be advised that <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is a chronic condition and they should adhere to their medication along with their National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Education Program (NCEP)-recommended diet, a regular exercise program as appropriate, and periodic testing of a fasting lipid panel to determine goal attainment.  </p>
<p><span class="Bold">Patients should be advised about substances they should not take concomitantly with atorvastatin [see Warnings and Precautions <a href="#LINK_74c7f9e1-26b7-4f7b-ae4d-75832e9bc4f8">(5.1)</a>]. Patients should also be advised to inform other healthcare professionals prescribing a new medication that they are taking atorvastatin calcium. </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_aacbded0-2cb1-4a57-a6ab-3b4fc3d94b90"></a><a name="section-16.1"></a><p></p>
<h2><span class="Bold">17.1 <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span> </span></h2>
<p class="First">All patients starting therapy with atorvastatin calcium should be advised of the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and told to report promptly any unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if these muscle signs or symptoms persist after discontinuing atorvastatin. The risk of this occurring is increased when taking certain types of medication or consuming larger quantities (&gt;1 liter) of grapefruit juice. They should discuss all medication, both prescription and over the counter, with their healthcare professional. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_64aa2c21-87be-4641-8e45-0031c329881c"></a><a name="section-16.2"></a><p></p>
<h2><span class="Bold">17.2 Liver Enzymes </span></h2>
<p class="First">It is recommended that liver enzyme tests be performed before the initiation of atorvastatin calcium and if signs or symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> occur. All patients treated with atorvastatin calcium should be advised to report promptly any symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine, or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9bb4b8b7-f7be-4101-84af-c4320d453a6a"></a><a name="section-16.3"></a><p></p>
<h2><span class="Bold"><span class="Bold">17.3 Pregnancy </span></span></h2>
<p class="First">Women of childbearing age should be advised to use an effective method of birth control to prevent pregnancy while using atorvastatin calcium. Discuss future pregnancy plans with your patients, and discuss when to stop atorvastatin calcium if they are trying to conceive. Patients should be advised that if they become pregnant, they should stop taking atorvastatin calcium and call their healthcare professional. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_434afcb6-4103-4058-86ba-9dc8a93f0886"></a><a name="section-16.4"></a><p></p>
<h2><span class="Bold">17.4 Breast-feeding </span></h2>
<p class="First">Women who are breastfeeding should be advised to not use atorvastatin calcium. Patients who have a lipid disorder and are breast-feeding, should be advised to discuss the options with their healthcare professional. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_127f0d82-5951-43bf-b88a-b2a8a364bab4"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">Atorvastatin Calcium Tablets</span></p>
<p>Read the Patient Information that comes with atorvastatin calcium tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or treatment. </p>
<p>If you have any questions about atorvastatin calcium tablets, ask your doctor or pharmacist. </p>
<p><span class="Bold">What is atorvastatin calcium tablet? </span></p>
<p>Atorvastatin calcium tablet is a prescription medicine that lowers <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in your blood. It lowers the LDL-C ("bad" <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>) and triglycerides in your blood. It can raise your HDL-C ("good" <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>) as well. Atorvastatin calcium tablets are for adults and children over 10 whose <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> does not come down enough with exercise and a low-fat diet alone.</p>
<p>Atorvastatin calcium tablets can lower the risk for <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, certain types of heart surgery, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> in patients who have heart disease or risk factors for heart disease such as: </p>
<ul class="Disk"><li>age, smoking, high blood pressure, low HDL-C, heart disease in the family. </li></ul>
<p>Atorvastatin calcium tablets can lower the risk for <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and risk factors such as: </p>
<ul class="Disk"><li>eye problems, kidney problems, smoking, or high blood pressure. </li></ul>
<p>Atorvastatin calcium tablets starts to work in about 2 weeks. </p>
<p><span class="Bold">What is <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>? </span></p>
<p><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> and triglycerides are fats that are made in your body. They are also found in foods. You need some <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> for good health, but too much is not good for you. <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> and triglycerides can clog your blood vessels. It is especially important to lower your <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> if you have heart disease, smoke, have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or high blood pressure, are older, or if heart disease starts early in your family. </p>
<p><span class="Bold">Who should not take atorvastatin calcium tablets? </span></p>
<p>Do not take atorvastatin calcium tablets if you: </p>
<ul class="Disk">
<li>are pregnant or think you may be pregnant, or are planning to become pregnant. Atorvastatin calcium tablets may harm your unborn baby. If you get pregnant, stop taking atorvastatin calcium tablets and call your doctor right away. 

</li>
<li>are breast feeding<span class="Bold">. </span>Atorvastatin calcium tablets can pass into your breast milk and may harm your baby. 

</li>
<li>have liver problems. 

</li>
<li>are allergic to atorvastatin calcium tablets or any of its ingredients. The active ingredient is atorvastatin. See the end of this leaflet for a complete list of ingredients in atorvastatin calcium tablets.  </li>
</ul>
<p>Atorvastatin calcium tablets have not been studied in children under 10 years of age. </p>
<p><span class="Bold">Before you start atorvastatin calcium tablets</span></p>
<p>Tell your doctor if you: </p>
<ul class="Disk">
<li>have <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> 

</li>
<li>drink more than 2 glasses of alcohol daily 

</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> 

</li>
<li>have a thyroid problem    

</li>
<li>have kidney problems </li>
</ul>
<p>Some medicines should not be taken with atorvastatin calcium tablets. Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Atorvastatin calcium tablets and certain other medicines can interact causing serious side effects. Especially tell your doctor if you take medicines for: </p>
<ul class="Disk">
<li>your immune system 

</li>
<li><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> 

</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> 

</li>
<li>birth control 

</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> 

</li>
<li>HIV or AIDS </li>
</ul>
<p>Know all the medicines you take.Keep a list of them with you to show your doctor and pharmacist. </p>
<p><span class="Bold">How should I take atorvastatin calcium tablets? </span></p>
<ul class="Disk">
<li>Take atorvastatin calcium tablets exactly as prescribed by your doctor. Do not change your dose or stop atorvastatin calcium tablets without talking to your doctor. Your doctor may do blood tests to check your <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels during your treatment with atorvastatin calcium tablets. Your dose of atorvastatin calcium tablets may be changed based on these blood test results.     </li>
<li>Take atorvastatin calcium tablets each day at any time of day at about the same time each day. Atorvastatin calcium tablets can be taken with or without food.</li>
</ul>
<p>Don't break atorvastatin calcium tablets before taking. </p>
<ul class="Disk">
<li>Your doctor should start you on a low-fat diet before giving you atorvastatin calcium tablets. Stay on this low-fat diet when you take atorvastatin calcium tablets . </li>
<li>If you miss a dose of atorvastatin calcium tablets, take it as soon as you remember. Do not take atorvastatin calcium tablets if it has been more than 12 hours since you missed your last dose. Wait and take the next dose at your regular time. Do not take 2 doses of atorvastatin calcium tablets at the same time. </li>
<li>If you take too much atorvastatin calcium tablets or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, call your doctor or Poison Control Center right away. Or go to the nearest emergency room. </li>
</ul>
<p><span class="Bold">What should I avoid while taking atorvastatin calcium tablets? </span></p>
<ul class="Disk">
<li>Talk to your doctor before you start any new medicines. This includes prescription and non-prescription medicines, vitamins, and herbal supplements. Atorvastatin calcium tablets and certain other medicines can interact causing serious side effects. 

</li>
<li>Do not get pregnant. If you get pregnant, stop taking atorvastatin calcium tablets right away and call your doctor. </li>
</ul>
<p><span class="Bold">What are the possible side effects of atorvastatin calcium tablets? </span></p>
<p><span class="Bold">Atorvastatin calcium tablets can cause serious side effects. These side effects have happened only to a small number of people. Your doctor can monitor you for them. These side effects usually go away if your dose is lowered or atorvastatin calcium tablets are stopped. These serious side effects include: </span></p>
<ul class="Disk"><li>
<span class="Bold">Muscle problems. </span>Atorvastatin calcium tablets can cause serious muscle problems that can lead to kidney problems, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>. You have a higher chance for muscle problems if you are taking certain other medicines with atorvastatin calcium tablets.  </li></ul>
<ul class="Disk"><li>
<span class="Bold">Liver problems.</span> Your doctor should do blood tests to check your liver before you start taking atorvastatin calcium tablets and if you have symptoms of liver problems while you take atorvastatin calcium tablets. Call your doctor <span class="Bold">right away </span>if you have the following symptoms of liver problems: 

<ul class="Circle">
<li>feel tired or week 

</li>
<li>loss of appetite 

</li>
<li>upper belly <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> 

</li>
<li>dark amber colored urine 

</li>
<li>yellowing of your skin or the whites of your eyes</li>
</ul>
</li></ul>
<p><span class="Bold">Call your doctor right away if you have</span><span class="Bold">: </span></p>
<ul class="Disk">
<li>muscle problems like <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that happen without a good reason, especially if you also have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or feel more tired than usual. This may be an early sign of a rare muscle problem. 

</li>
<li>muscle problems that do not go away even after your doctor has advised you to stop taking atorvastatin calcium tablets. Your doctor may do further tests to diagnose the cause of your muscle problems. 

</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing which may require treatment right away. 

</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. 

</li>
<li>passing brown or dark-colored urine. 

</li>
<li>you feel more tired than usual 

</li>
<li>your skin and whites of your eyes get yellow. 

</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>. 

</li>
<li><span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span>.  </li>
</ul>
<p>In clinical studies, patients reported the following common side effects while taking atorvastatin calcium tablets: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, muscle and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, and alterations in some laboratory blood tests.  </p>
<p>The following additional side effects have been reported with atorvastatin calcium tablets: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, tendon problems, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</p>
<p>Talk to your doctor or pharmacist if you have side effects that bother you or that will not go away.  </p>
<p>These are not all the side effects of atorvastatin calcium tablets. Ask your doctor or pharmacist for a complete list.</p>
<p><span class="Bold">How do I store atorvastatin calcium tablets</span></p>
<ul class="Disk">
<li>Store atorvastatin calcium tablets at 20° - 25°C (68° - 77°F) [see USP Controlled Room Temperature]. 

</li>
<li>Do not keep medicine that is out of date or that you no longer need. 

</li>
<li>
<span class="Bold">Keep atorvastatin calcium tablets and all medicines out of the reach of children. </span>Be sure that if you throw medicine away, it is out of the reach of children. </li>
</ul>
<p><span class="Bold">General information about atorvastatin calcium tablets</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use atorvastatin calcium tablets for a condition for which it was not prescribed. Do not give atorvastatin calcium tablets to other people, even if they have the same problem you have. It may harm them. </p>
<p>This leaflet summarizes the most important information about atorvastatin calcium tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about atorvastatin calcium tablets that is written for health professionals. </p>
<p><span class="Bold">What are the Ingredients in atorvastatin calcium tablets?</span></p>
<p><span class="Bold">Active Ingredient: </span>atorvastatin calcium </p>
<p><span class="Bold">Inactive Ingredients:</span> Basic butylated methacrylate copolymer, crospovidone, hydroxy propyl cellulose, lactose monohydrate, magnesium stearate, methanol, microcrystalline cellulose, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and sodium lauryl sulphate. The tablet coating contains lecithin, polyvinyl alcohol, talc, titanium dioxide, and xanthan gum.</p>
<p>To reorder additional Patient Information Sheets contact Dr. Reddy's Customer Service at 1-866-733-3952.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e885ff52-69b7-402b-8769-a59f56eca3fc"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First">Rx Only                                                                                                </p>
<p>Manufactured by:</p>
<p><span class="Bold">Dr. Reddy’s Laboratories Limited</span></p>
<p>Bachupally - 500 090 INDIA </p>
<p>Revised: 0614    </p>
<p>150056745</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_1732d2b3-a217-4846-b671-ebcaee157461"></a><a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Principal Display Panel-Atorvastatin Calcium Tabs 80mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8f71bea6-2fd0-44ae-afd9-727d365293a0&amp;name=atorvastatin-calcium-tablets---80mg-5.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ATORVASTATIN CALCIUM 		
					</strong><br><span class="contentTableReg">atorvastatin calcium tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0615-7772(NDC:55111-124)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM TRIHYDRATE</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN</td>
<td class="formItem">80 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LECITHIN, SOYBEAN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RDY;124</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0615-7772-05</td>
<td class="formItem">15  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0615-7772-39</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202357</td>
<td class="formItem">07/17/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>NCS HealthCare of KY, Inc dba Vangard Labs
							(050052943)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NCS HealthCare of KY, Inc dba Vangard Labs</td>
<td class="formItem"></td>
<td class="formItem">050052943</td>
<td class="formItem">RELABEL(0615-7772), REPACK(0615-7772)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>438c5c78-d15c-4b74-abbc-7485aba00c69</div>
<div>Set id: 8f71bea6-2fd0-44ae-afd9-727d365293a0</div>
<div>Version: 6</div>
<div>Effective Time: 20150126</div>
</div>
</div> <div class="DistributorName">NCS HealthCare of KY, Inc dba Vangard Labs</div></p>
</body></html>
